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Project Title 
Molecular characterisation of acute intermittent porphyria in South Africa. 
 
Short Description of the Project 
Acute intermittent porphyria belongs to a group of inherited disorders of haem metabolism.  The 
object of this project is to characterise the mutations in the hydroxymethylbilane synthase 
(HMBS) gene in a cohort of South African patients. The elucidation of these mutations will 
facilitate an understanding of the molecular basis of AIP in South Africa, and provide a platform 
for the screening of family members of affected patients. Identification of latent carriers would 
allow for education with respect to precipitants and how best to avoid them, so as to minimise 
the risk of provoking an acute attack. 
 
Project Details 
Aims 
1. To understand the molecular basis of acute intermittent porphyria (AIP) in South 
Africa: specifically, this project aims to investigate the specific DNA sequence 
variations in the HMBS gene that exist in South African patients with AIP. 
2. To determine the relative incidence of HMBS gene mutations in a South African 
cohort. 
3. To provide a basis for genetic screening and counseling for AIP families in South 
Africa. 
 
Objectives 
1. Collect whole blood samples/culture stored Epstein-Barr virus (EBV) transformed 
lymphoblasts from AIP patients, and extract DNA. 
2. Design primers to cover exons and surrounding introns of the HMBS gene using 
oligonucleotide design software. 
3. Amplify, using polymerase chain reaction (PCR), all 15 exons (and surrounding 
introns) of the HMBS gene. 
4. Directly sequence PCR products to identify any sequence variations 
(mutation/polymorphisms). 
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5. Compare identified mutations/polymorphisms with those published for AIP 
cohorts in other countries. 
6. Based on results obtained above, establish restriction enzyme analyses where 
possible, to enable easy screening. 
7. Screen family members and construct family pedigrees. 
8. Provide appropriate genetic counseling. 
9. Perform similar analyses, on an on-going basis, on newly diagnosed AIP patients 
that may present during the study period and thereafter. 
10. Publish findings in an international peer-reviewed journal and as a MMed 
dissertation (Dr P. Fortgens). 
 
Background 
The porphyrias are a heterogeneous group of genetic disorders of haem biosynthesis. They 
have two characteristic clinical symptoms: the acute attack and/or photocutaneous 
sensitivity. There are eight enzymes in the pathway, and partial defects in each of these 
may result in a specific type of porphyria each with a characteristic build up of porphyrins 
with or without the precursors 5-aminolaevulinic acid (ALA) and porphobilinogen 
(PBG).1, 2 There are two groups of porphyria viz. the acute and non-acute porphyrias. The 
distinction between these two groups appears to be the potential or non-potential for the 
precursors ALA and PBG to accumulate (only in the acute porphyrias will the precursors 
accumulate). Photosensitivity appears to be associated with the accumulation of the 
porphyrinogens or their oxidized forms, the porphyrins. 
 
There are four acute porphyrias. These acute porphyrias are distinguished by the 
occurrence of potentially fatal acute neurovisceral attacks. One of these, acute intermittent 
porphyria (AIP), is an autosomal dominant disorder resulting from partially defective 
porphobilinogen deaminase (PBGD, also known as HMBS), the third enzyme in the haem 
biosynthetic pathway. In South Africa, AIP is found in all population groups, and is under 
diagnosed in the black population.3 Worldwide, AIP is the most common of the 
neurological porphyrias with an estimated prevalence of 1-8 per 100 000. Indeed, even in 
South Africa where there is a well documented preponderance of another one of the acute 
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porphyrias, variegate porphyria, AIP acute attacks make up the majority of acute attack 
admissions in South African hospitals.4 
 
While most people with AIP remain clinically and biochemically normal throughout their 
lives, potentially fatal acute neurological symptoms may be triggered (often by 
porphyrinogenic drugs, or in the case of females, hormonal fluctuations). Hence the 
importance of identifying individuals with the disease, and thus susceptible to the acute 
attack. The most sensitive and specific diagnosis in these individuals and their families is 
through molecular (mutational) analysis. Indeed, prior identification of individuals at risk 
is a good strategy in preventing acute attacks.5 Furthermore, AIP frequently poses a 
diagnostic and therapeutic challenge to clinicians. 
 
Worldwide, molecular heterogeneity of mutations causing AIP has been demonstrated. 
Over 300 mutations have been described in the HMBS gene, but only 8 of these mutations 
have been identified in the ubiquitous form of the enzyme alone.6, 7 Mutations are equally 
distributed throughout the HMBS gene with no prevalent sites for mutation having been 
identified.8 
 
In South Africa AIP remains poorly documented and only 5 mutations (Arg26His, 
Arg116Trp, Arg173Gln, c.771_772insThr and c.1002delGly) have been identified to date 
by workers abroad, in collaboration with earlier workers in our laboratory.9, 10 Clearly the 
molecular characterization of other HMBS gene defects in South African individuals will 
be of interest to researchers in the field and of benefit to the patients and their relatives. 
The HMBS gene is located on chromosome11q23.3 and comprises 15 exons.11 Two forms 
(erythroid specific and ubiquitous) of PBGD are generated by the use of separate 
promoters and alternative splicing of the two primary transcripts.12 These forms differ at 
the amino-terminal ends where the ubiquitous form extends by another 17 amino acid 
residues.13 
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Methodology 
Study design 
Identification of disease causing mutations and polymorphisms will be undertaken in a 
cohort of South African AIP patients identified in our Lennox Eales (University of Cape 
Town) Porphyria Laboratories. DNA will be extracted, the exons of the HMBS gene 
amplified by PCR and the exact mutation identified by sequencing. Restriction analysis 
will be set up to identify the presence/absence of the mutation in other family members. 
Family pedigrees will be also be constructed. The methodology proposed above has been 
successfully utilized for mutation detection in the past both in our and other laboratories.  
 
A three year time frame in which to complete the study is realistic. The project will be 
performed in the Lennox Eales (University of Cape Town) Porphyria Laboratories which 
are internationally recognized for their contribution to research in the field of porphyria. 
They offer a good existing infrastructure for biochemistry and molecular studies. Together 
with clinicians in the Departments of Medicine at the University of Cape Town (Prof 
Spearman and Drs Sonderup and Hairwadzi) and the University of Kwa-Zulu Natal, these 
laboratories are dedicated to offering a comprehensive service to the porphyria community 
of South Africa: patients, medical practitioners and scientists alike. They are headed by 
Professor Meissner who is internationally recognised as a world authority in the field of 
porphyria. Dr Corrigall has many years of experience in the Liver Centre and porphyria 
laboratories, specializing in protein purification and molecular biology, and is also 
internationally recognised. These laboratories house the equipment required to carry out 
this study. In addition, use will be made of the sequencing facility at the University of 
Stellenbosch (Department of Genetics). All aspects of this research will conform to the 
requirements of the Declaration of Helsinki (World Medical Association, revised 2008). 
 
Characteristics of the study population 
Approximately 15 AIP patients from all racial groups, identified through our laboratories 
and the Liver Clinic at Groote Schuur Hospital/University of Cape Town will be studied. 
In addition, these probands will most likely give rise to approximately 60 family members 
for testing. It is not possible to give an exact number of participants as, as further AIP 
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families who are identified at the clinic over the 3 year period of the study, will be 
included. Likewise, it is impossible to estimate the precise size of patient families and how 
many of those will consent to testing. 
 
Informed consent will be obtained from the parents of individuals under the age of 7 
years. Minors over the age of 7 years will be asked to fill in the consent forms for minors. 
Adults with impaired decision making capacity and people in unequal relationships will 
not be included in the study.  
 
Inclusion and exclusion criteria 
AIP patients will be recruited and consent requested after a biochemical diagnosis of AIP 
has been made (see research procedure and data collection methods). Likewise, their 
family members will be recruited once the proband mutation has been identified. Subjects 
from all ethnic groups in South Africa will be included. The participants will be chosen 
after a discussion between the 3 primary investigators, and with consultation of 
participating medical consultants if necessary. 
 
Recruitment and enrolment 
The University of Cape Town Porphyria laboratories have a number of previously 
identified patients (12), and approximately 3 new patients per year are identified. We will 
be re-contacting patients with a previous diagnosis of AIP through the Liver Clinic, as 
well as investigating any new AIP patients who may be identified during the course of the 
study. The point of re-contacting patients will be to ask consent to use their blood samples 
(already obtained for routine porphyrin analyses in our labs) for further DNA analysis. In 
the case of newly identified patients, consent will be requested at the time of diagnosis. 
Once mutation(s) have been identified, blood samples from consenting family members 
will also be requested and obtained. 
 
We have in storage at -180oC a number of EBV transformed lymphoblast cultures from 
previously identified AIP patients. These may be cultured and DNA extracted, to provide 
suitable DNA for analysis, in which case drawing of further blood from these patients will 
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not be necessary. Any patient enrolled in the study will be asked to participate in the study 
by the Liver Clinic physicians or Dr Fortgens. They will be informed of the study, and 
given an information sheet and requested to read it, prior to giving consent. Subject to 
agreement to participate in the study, blood will be taken from them for study. 
 
The following information will be collected and stored for each family: identifying and 
demographic data, full clinical and family history and, where possible and appropriate, 
further clinically relevant information including physical examination findings, 
biochemistry and haematology will be entered into a computerized database. 
 
Research procedures and data collection methods 
The diagnosis of AIP in probands is based on measurement of standard porphyrin 
biochemistry (raised uroporphyrin in the urine and raised precursors (ALA and PBG), a 
plasma porphyrin emission scan peak at 619nm together with a typical AIP clinical history 
(no photosensitive skin disease/potential and a history of acute neurovisceral attacks). We 
will further characterise patients with AIP in South Africa by DNA analysis to identify the 
disease-causing mutation present in each family. Dr Anne Corrigall has considerable 
experience in all the techniques required for this project apart from the sequencing. As 
mentioned previously this will be performed at the University of Stellenbosch. 
Dr Fortgens will be trained in all the techniques by Dr Corrigall. 
 
Collection of blood samples from patients and cell culture 
Following informed consent, blood samples will be obtained by venepuncture from known 
AIP patients, either at the Liver Clinic at Groote Schuur Hospital, or by arrangement with 
Dr Fortgens, or through a peripheral pathology laboratory if the subject is not based in 
Cape Town. Blood samples (2X ethylenediaminetetraacetic acid blood tubes, total 9ml) 
will be drawn by a qualified medical or nursing professional.  
 
Control samples 
We will make use of approximately 50 existing control DNA samples, drawn from a 
previous porphyria molecular study, stored within the Porphyria Laboratory. These were 
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drawn from blood donors and hospital staff, are anonymous and irretrievably dissociated 
from the identities of their donors. If additional control samples are necessary, these will 
be drawn with the consent of the donors, will be irretrievably anonymised and the donors 
informed of this. 
 
DNA extraction 
DNA will be extracted and isolated from cultured lymphoblasts (previously stored 
at -180oC) or directly from whole blood (9ml) using the Promega DNA extraction kit. 
 
Primer design 
Primers will be designed using oligonucleotide designer software (Primer Designer) and 
checked for suitability by Oligoanalyzer, Blast and ePCR. 
 
PCR amplification 
Primers will be designed to cover all 15 exons of the HMBS gene and their surrounding 
introns. PCR amplification will be carried out in a total volume of 50µL containing 10mM 
Tris, 1.5mM magnesium chloride, 0.2units GoTaq flexi polymerase (Promega), 50µM of 
each deoxynucleotide, 0.5µM of each primer and 100ng of genomic DNA. The cycles will 
consist of an initial denaturation step at 95oC for 1 min, 35 cycles of denaturation at 95oC 
for 30s, annealing at relevant temperatures for 30s, and extension at 72oC for 30sec, and 
then final extension for 7min at 72oC followed by cooling at 4oC for 6min. This is 
performed in a Robocycler Thermal cycler. If necessary the amplification conditions will 
be altered to accommodate the primers. 
 
Direct sequencing 
PCR products, after verifying with polyacrylamide electrophoresis for specificity, will be 
purified using the GFX Amersham purification kit and sent to the University of 
Stellenbosch Central Sequencer for capillary zone electrophoresis-based sequence 
analysis. 
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Once a mutation has been identified restriction analysis will be set up, if possible, to 
enable easy screening of other family members and control individuals. Approximately 
fifty controls, representative of the ethnicity of the patients, will be selected and 
investigated for the presence of sequence variations/mutations identified during the course 
of the study. 
 
Data safety and monitoring 
Security and confidentiality will be maintained, and no person other than the principal 
researchers will have access to the information entered into the computerized database and 
laboratory workbooks. No adverse events are expected. 
 
Data analysis  
Sequencing will be performed at the sequencing facility at the University of Stellenbosch, 
which has an excellent track record for good quality and reliable sequencing. Sequencing 
will be performed in both a forward and reverse direction (two different PCR amplicons) 
to confirm the exact mutation. After identification of the disease causing mutation and any 
polymorphisms in each family, data will be closely examined and assessed for any 
potential founder effect. Clinical, biochemical and molecular data will be evaluated and 
correlated after examination of the clinical and biochemical database. Pedigrees will be 
constructed in the families. 
 
Description of Risks and Benefits 
The participants in this study are not subjected to risk. Benefits to the patients will be a 
definitive and 100% specific and sensitive diagnosis of AIP, identification of latent cases 
(i.e. gene carriers who may unknowingly be at risk of the acute attack) and hence advice 
can be given on how to avoid precipitating an acute attack. 
 
Informed Consent Process 
Previous consent 
Existing EBV transformed lymphoblasts were collected for porphyria diagnosis and 
characterisation thereof, approximately 15-20 years ago. In each case, verbal consent was 
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given for lymphoblasts to be transformed and stored indefinitely for future DNA analysis 
assuming such analysis became possible. Collection of such blood samples fell within the 
definition of basic standard of care since both biochemical and DNA blood analysis are 
regarded as integral to the diagnosis of AIP. 
 
Prospective consent 
We acknowledge that current guidelines for consent require a more formalized process. 
Any further subjects we identify for possible inclusion in our study, their families, and 
family members of already identified AIP patients, will provide full informed consent in 
writing, using consent forms (Part D). Informed consent will be ongoing throughout the 
study. Any minor who does not wish to give participate in the study will not be 
pressurized in any way to do so. Consent will be obtained by Dr Philip Fortgens, 
Prof Spearman, Dr Sonderup or Dr Hairwadzi. Consent forms will be translated into 
Afrikaans and Xhosa as required. 
 
Comprehension of information 
All potential participants will have a one-on-one discussion with a medical doctor 
involved in the study. They will be given an information sheet which they will be required 
to read prior to signing the consent form. If a subject appears not to understand the 
medical doctor will explain further. 
 
Withholding information 
No information will be withheld from participants in the study. 
 
Consent and assent forms 
See attached forms (Part D). Different forms will be used for adults and minors (age 7-17 
years).  Once the forms have been approved by the ethics committee, they will be 
translated into Afrikaans and Xhosa. 
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Privacy and Confidentiality 
Strict regulations for patient confidentiality will be adhered to. Subject information will be 
recorded in a database for sole use by the principal researchers involved in the study. 
Patients names will be encoded and not appear on sample tubes used during the study. 
 
Reimbursement for Participation 
The participants in the study will not receive any financial reimbursement for 
participation, but travel costs will be covered as necessary. 
 
Emergency Care and Insurance for Research-Related Injuries 
No research related injuries are expected in this study. 
 
What Happens at the End of the Study 
Patients and family members will be informed of the findings of the study (providing they 
wish to know the outcome). Appropriate clinical management will be discussed with 
patients and genetic counseling will be offered. 
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Envisaged Outputs/Outcomes 
This study will allow for the molecular characterisation of AIP in a South African cohort 
of patients, the screening of family members and the counseling of individuals found to 
have mutations. It is envisaged that this work be presented at the International Congress of 
Porphyrins and Porphyrias 2013 (Luzern, Switzerland) and at the South African 
Laboratory Medicine Congress 2013 in Cape Town. Both of these objectives have 
subsequently been met. The study will further provide material for Dr Fortgens’ MMed 
dissertation and will also provide an opportunity to publish the results in a peer-reviewed 
journal.  
 
Institutional Approval  
This proposal has been approved by the University of Cape Town Research Ethics 
Committee. 
 
Funding 
Funding is provided by the Medical Research Council, self-initiated research grant 
awarded to PN Meissner, the NRF Incentive award for rated researchers (PN Meissner), 
The University of Cape Town Research Committee and the National Health Laboratory 
Service Research Trust. 
	   24	  
Amendments to Original Protocol 
 
 
1. EBV-transformed lymphoblasts from AIP patients were not used as stored DNA was 
found to be of suitable quality for further study. 
2. The number of AIP patients and their family members was initially over-estimated due 
to difficulties in subsequently tracing them.  Access to families, particularly in remote 
locations was also challenging, hence tracing of relatives and the generation of 
pedigrees was not part of this study. 
3. During the study the Robocycler Thermal cycler was replaced by the Labnet Mutigene 
Optimax necessitating the re-optimisation of some PCR reactions. 
4. PCR products were visualized using both polyacrylamide and agarose gel 
electrophoresis systems. 
5. PBGD enzyme activity was measured in a patient with clinical and biochemical 
parameters consistent with AIP, but where mutation analysis showed no abnormality. 
6. Aim 2 of the study (to determine the relative incidence of HMBS gene mutations in a 
South African cohort) revealed itself to be beyond the scope of the study for MMed 
purposes. 
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Literature Review: Acute Intermittent Porphyria 
 
 
INTRODUCTION 
The porphyrias are a group of largely inherited metabolic diseases, each characterised by 
impairment of a specific enzymatic step in haem biosynthesis. This results in the accumulation of 
haem precursors and the manifestation of characteristic clinical features (1).  This literature 
review serves firstly to introduce the porphyrias as a group, then focus on acute intermittent 
porphyria (AIP; OMIM 176000), the mutations associated with this disease, and finally to 
discuss its importance in the South African context. 
 
There are eight enzymes involved in haem biosynthesis (Figure 1), and a defect at any one of 
these steps can result in a characteristic accumulation of porphyrins with or without the haem 
precursors 5-aminolaevulinic acid (ALA) and porphobilinogen (PBG).  The word “porphyria” is 
derived from the Greek word porphuros meaning purple, which alludes to the typical 
discolouration of urine in patients with porphyria.  It is often cited that Hippocrates (460-
375 BC) was the first to recognise porphyria, but the first cases of the appearance of human 
urinary porphyrin pigments in modern scientific literature was reported in 1874 (2, 3).  
Thereafter, in 1889, a Dutch physician Stokvis, described a woman with dark-red urine who died 
after taking the hypnotic Sulfonal (4). This is commonly thought to be the first description of the 
acute attack of porphyria. 
 
HAEM BIOSYNTHESIS 
While haem synthesis is necessary for all mammalian cells that obtain energy from 
mitochondrial fuel oxidation, the major producers are the liver for the synthesis of haemoproteins 
(mitochondrial or microsomal cytochromes, peroxidase, catalase, tryptophan pyrrolase enzymes, 
amongst many) and erythropoietic cells chiefly for the production of haemoglobin (5).  The first 
enzyme in the biosynthetic pathway, 5-aminolaevulinic acid synthase (ALAS; Enzyme 
Commission (EC) number 2.3.1.37), is coded by two tissue-specific genes (6).  The ubiquitously 
expressed ALAS1 (on chromosome 3) is regarded as a house-keeping gene for the synthesis of 
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haemoproteins, while ALAS2 (on chromosome X) is expressed only in erythroid cells for 
haemoglobin production.  Approximately 80% of haem synthesis occurs in the bone marrow and 
about 15% in the liver.  Indeed, regulation of the pathway is tissue and cell specific, subject to 
modulation by a variety of developmental and environmental pressures through diverse 
transcriptional factors and mechanisms (7).  In general, however, as is typical for many 
biosynthetic pathways, synthesis of the first committed intermediate, in this case the generation 
of ALA by ALAS, is considered rate-limiting.  ALAS2 transcription is induced during active 
haemoglobin synthesis, a process co-ordinated by transcription factors according to the state of 
cell maturation (8).  Unlike ALAS2, the ubiquitously expressed ALAS1 transcript is subject to 
negative feedback regulation by intra-cellular haem (9), and can further be induced by a number 
of other factors, including starvation, drugs and hormones.  Indeed,  peroxisome proliferator-
activated receptor γ coactivator-1α (PGC-1α) is induced under conditions of energy depletion 
and, in turn, is able to up-regulate mitochondrial biogenesis, gluconeogenic enzymes and the 
transcription of ALAS1 (10).  The latter probably occurs to increase the synthesis of 
mitochondrial respiratory haem proteins, thereby allowing more efficient energy utilisation. 
 
Haem biosynthesis (Figure 1) commences in the mitochondrion with two simple compounds, 
glycine and succinyl CoA.  The first reaction, catalyzed by ALAS, using pyridoxal phosphate 
(vitamin B6) as co-factor, results in the formation of ALA.  The second reaction occurs in the 
cytosol during which 2 molecules of ALA condense to form a monopyrrole, PBG, eliminating 
two molecules of water.  This is catalyzed by the enzyme ALA dehydratase (EC 4.2.1.24) and 
requires zinc as co-factor.  Next, PBG deaminase (PBGD; EC 2.5.1.61), also known as 
hydroxymethylbilane synthase, catalyzes the condensation of 4 molecules of PBG with the 
release of 4 molecules of ammonia to form hydroxymethylbilane, a linear tetrapyrrole.  During 
the fourth reaction, uroporphyrinogen (UPG) III synthase (EC 4.2.1.75) is responsible for closing 
the tetrapyrrole ring and catalyzing isomerisation to UPG III, containing 8 carboxyl groups on 
the side chains.  Non-enzymatic cyclization to the I isomer can occur.  Sequential 
decarboxylation by UPG decarboxylase (EC 4.1.1.37) through 7, 6 and 5 carboxyl groups occur 
to generate the 4 carboxyl coproporphyrinogen (CPG) III.  The remainder of the pathway, 
including the final haem producing reaction, occurs within the mitochondrion. 
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The sixth reaction consists of the oxidative decarboxylation of CPG III to form the dicarboxylic 
protoporphyrinogen IX via the enzyme CPG oxidase (EC 1.3.3.3).  The penultimate step 
involves the enzymatic oxidation of protoporphyrinogen IX to protoporphyrin IX by 
protoporphyrinogen oxidase (EC 1.3.3.4).  Ferrochelatase (EC 4.99.1.1) catalyzes the final 
reaction which uses ferrous iron and protoporphyrin to produce haem. 
 
The fundamental defect in all porphyrias is the overproduction of haem intermediates resulting in 
the clinical sequelae of the disease.  Porphyrias may be classified as either erythropoietic or 
hepatic, based on the organ from which precursors arise (Figure 1).  From a clinical perspective, 
however, it is more useful to divide porphyrias into those causing acute attacks, those resulting in 
cutaneous lesions, and the rare autosomal recessive porphyrias.  The remainder of this review 
will focus on AIP, including clinical aspects of presentation and diagnosis, and will also address 
the molecular pathology of this disease. 
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Figure 1: Haem biosynthetic pathway and the porphyrias 
Light grey boxes: hepatic porphyrias; dark grey boxes: erythropoietic porphyrias; white boxes: 
intermediates. 
ALAD: ALA dehydratase; PBGD: PBG deaminase; UROIIIS: uroporphyrinogen III synthase; 
UROD: uroporphyrinogen decarboxylase; CPO: coproporphyrinogen oxidase; PPOX: 
protoporphyrinogen oxidase;  FECH: ferrochelatase (reproduced from (11)).  
 
ACUTE INTERMITTENT PORPHYRIA 
AIP is the most common and severe of the inherited acute porphyrias world-wide, and is 
classified as a hepatic porphyria due to the overproduction of PBG (and ALA and other 
porphyrin intermediates) in the liver.  The disease belongs to a group of autosomal dominantly 
inherited acute porphyrias, which include variegate porphyria and hereditary coproporphyria but 
these, unlike AIP, are also characterised by cutaneous involvement. An extremely rare, fourth 
acute porphyria also exists and is termed ALAD deficiency porphyria. Like AIP it only manifests 
with acute porphyria symptoms.  AIP results from a partial deficiency of the third enzyme in the 
haem biosynthetic pathway, PBGD.  Markedly elevated ALA and PBG occur during an acute 
attack, and often mildly elevated PBG during remission.  Urinary porphyrins are also frequently 
raised. 
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The European Porphyria Network recently collected information over a 3 year period regarding 
the number of newly diagnosed patients with an inherited porphyria.  The study received 
information from 335 patients in 11 different European countries, and showed that the disease 
occurs in many population groups, with an incidence of symptomatic AIP of 0.13 per year per 
million population.  In northern Sweden, due to a founder effect, the incidence is as high as 0.51 
per year per million (12).  The prevalence of 5.4 per million (12) is significantly lower than the 
50 per million stated in the United States of America (Anderson 2001).  AIP has also been 
reported in patients of African and Afro-Caribbean extraction (13). 
 
Acute porphyrias manifest more commonly in women than men, and rarely occur before puberty 
or after menopause (14).  Most patients who develop the phenotype have only a few attacks and 
then remain symptom free for the rest of their lives.  Indeed, about 80-90% of patients who 
inherit the defective autosomal dominant AIP gene remain clinically latent for life (15), 
reflecting the poor penetrance of this disease. Severe, recurrent acute attacks of porphyria occur 
in a minority of patients and, in women, may be related to the menstrual cycle, particularly 
during the luteal phase when progesterone is elevated (16). 
 
Porphobilinogen Deaminase Protein 
PBGD is a cytosolic protein which catalyses the sequential condensation of four molecules of 
PBG in a linear head-to-tail fashion, with a covalent enzyme-intermediate at each step.  This 
yields the tetrapyrolle intermediate, hydroxymethylbilane, which is converted to 
uroporphyrinogen III by uroporphyrinogen III synthase.  In the absence of this enzyme, 
hydroxymethylbilane is able to undergo spontaneous cyclisation to the uroporphyrinogen I 
isomer.  PBGD has an interesting mechanism in which activity is dependent upon a 
dipyromethane co-factor which is bound covalently to a cysteine residue, and serves as an 
attachment site for subsequent PBG molecules (17, 18).  The co-factor is generated from PBG 
itself, but does not undergo catalytic turnover.  The human structure of PBGD (Protein Data 
Bank code: 3EQ1 and 3ECR) reveals a monomeric enzyme composed of three domains namely: 
I (N-terminal), II (central), and III (C-terminal).  The active site is located in a cleft between 
domains I and II and contains the dipyrromethane cofactor (19, 20). 
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Hydroxymethylbilane synthase Gene 
The human HMBS gene consists of 15 exons spanning over 10kb of genomic DNA, and is 
located at chromosome 11q23.3.  Two tissue specific mRNA isoforms arising from this single 
gene have been characterised; the two transcripts arise from two separate promoters via 
alternative splicing of exons 1 and 2 (Figure 2). The mRNA of the housekeeping (tissue non-
specific) isoform contains exons 1 and 3 to 15, which code for an enzyme of 361 amino acids 
(Mr 42 000), whereas the erythroid isoform is encoded by exons 2 to 15 and thus lacks the first 
17 amino acids of the NH2-terminus (Mr 40 000).  Eleven of these amino acids are encoded for 
by exon 1, and 6 by a short sequence which precedes the start codon of the erythroid isoform.  
The upstream promoter is active in all tissues while the second promoter, located 3kb 
downstream, is active only in erythroid cells (1, 5, 21).  Two erythroid trans-acting factors, 
GATA-1 and NF-E2, recognise sequences in the downstream HMBS promoter, suggesting a role 
for these transcription factors during erythroid development (22). 
 
Prior to the advent of DNA technology, AIP mutations were divided between two sub-types 
dependent upon the relative amounts of enzyme activity versus immunologically reactive protein 
in erythrocytes.  A mutation was classified as cross-reactive immunological material (CRIM)-
negative when the amount of immunoreactive protein corresponded to the amount of 
enzymatically active protein (1, 23, 24).  CRIM-negative mutations were further sub-divided into 
two groups according to PBGD activity.  In type I mutations, both enzyme activity and protein 
content are reduced by approximately 50%, as a result of the mutation rendering the mRNA or 
its protein product unstable.  This group (Type I) accounts for about 85% of all mutations, and 
results from nonsense and missense mutations, small deletions and insertions, splicing defects or 
polypeptide truncation.  Type II mutations arise from single base substitutions at the intron/exon 
boundary of exon 1, resulting in a splicing defect in the non-specific form of PBGD.  Erythroid-
specific PBGD is unaffected, as the mutation is upstream from the gene transcription initiation 
site.  The level of erythrocyte PBGD activity is, therefore, normal while activity in non-erythroid 
tissue (e.g. liver) is half normal.  Fewer then 5% of patients with AIP reveal this type of 
mutation.  Type III mutations are CRIM-positive, and produce an approximately 50% decrease 
in enzyme activity in the presence of normal levels of structurally stable but catalytically inactive 
enzyme.  These mutations occur mostly in exon 12, resulting in a catalytically impaired but 
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stable mutant due to abnormal splicing (25), or in exon 10 which encodes a well conserved 
region that is thought to be essential for catalytic activity (18). 
 
To date 390 mutations in the HMBS gene have been reported (Human Gene Mutation database; 
http://hgmd.org; last accessesed January 2014), with most being private and described in only 
one or a few families.  There are, however, several ‘founder effect’ populations based on the 
high prevalence of specific mutations in several geographical areas including Sweden, Canada, 
the Netherlands and Argentina (5, 12).  To date ten patients in South Africa have had a diagnosis 
of AIP confirmed at the gene level, of whom four carry the p.Arg116Trp mutation (26-28), 
described as occurring commonly in the Netherlands due to a founder effect (29).  The ancestry 
of three of these patients suggests mixed Malay, European and Khoi genetic makeup.  The 
European component may well be Dutch, thereby explaining the presence of this mutation in 
these apparently unrelated patients.  There is also a group of extremely rare recessive mutations 
of the HMBS gene, which manifests in early childhood.  The clinical presentation is different 
from that seen in dominant AIP, with features including mental and developmental retardation, 
cataracts, ataxia and convulsions (30). 
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Figure 2: Structure of the human HMBS gene and the tissue non-specific and erythroid-
specific transcripts 
PH: housekeeping promoter; PE: erythroid promoter.  The exons and introns are drawn to scale 
(reproduced from (21)). 
 
Clinical Aspects of AIP 
The clinical manifestations of an acute porphyric attack all result from extensive involvement of 
the peripheral, autonomic or central nervous systems.  Such neurological involvement may be 
due to axonal degeneration rather than demyelination (1).  An attack often begins with a 
prodromic phase, which may include behavioural changes such as restlessness, anxiety and 
insomnia (31).  The cardinal  feature of the attack is  abdominal pain which is severe and 
generalised, shows no signs of peritonism, and may be accompanied by other gastrointestinal 
symptoms such as nausea, vomiting and constipation.  Pain may also be experienced in the chest, 
back or thighs.  It is continuous and not cramping or colicky, and is usually severe enough to 
warrant opioid analgesia.  Signs of increased sympathetic activity such as tachycardia, sweating 
and hypertension may be present.  Urine may be dark in colour (orange or red) due to the 
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presence of porphobilin, an auto-oxidised product of PBG, and due to non-enzymatic cyclisation 
of PBG to form uroporphyrin I (5). 
 
Pain in the extremities is often described as muscular, and may reflect early peripheral 
neuropathy.  Not all patients with an acute attack will develop peripheral neuropathy, but it often 
occurs as a consequence of ingestion of harmful drugs (see below for further discussion on 
“Precipitating factors”).  Although almost any type of neuropathy can occur, motor neuropathies 
predominate and generally begin in proximal muscles, affecting arms more frequently than legs.  
Weakness can be symmetrical, asymmetrical, or localised, and nerve involvement may be 
progressive, giving rise to quadriplegia, cranial nerve (mostly seventh and tenth) palsies, 
respiratory and bulbar paralysis and death.  Seizures may also occur, thereby producing a 
therapeutic conundrum as many anti-epileptic drugs themselves exacerbate acute porphyria.  
Seizures may occur as a result of the porphyria itself or hyponatraemia.  Central nervous system 
involvement is uncommon, although cerebellar and pyramidal signs, transitory blindness and 
alterations in the level of consciousness do occur (1, 5, 11).  There has been a widely held belief 
that porphyrias are associated with chronic psychotic illnesses such as schizophrenia and bipolar 
mood disorder. There is, however, no evidence to support this contention (32), although 
disturbances such as anxiety, depression, acute paranoia and hallucinations do occur (33). 
Posterior reversible encephalopathy syndrome is a well-described feature of acute porphyria (33) 
and may occur due to abnormal cerebral autoregulation or cerebral endothelial dysfunction. 
 
Hyponatraemia is a common electrolyte abnormality during an acute attack, and may be severe.  
The syndrome of inappropriate anti-diuretic hormone secretion is often suggested as the 
aetiology, but salt depletion from vomiting with poor intake and salt-losing nephropathy are 
further possible mechanisms (1, 16).  Other organ systems may also be affected, causing chronic 
abnormalities of liver function and increased risk of hepatocellular carcinoma (34).  
Interestingly, Swedish patients with AIP have a higher risk of hepatocellular carcinoma than 
other AIP populations, an observation which may, in part, be explained by the high penetrance 
W128X mutation (35).  Whether this finding is generalisable to all AIP patients, and whether 
global screening of AIP patients will improve outcomes, is unclear (36).  Long-standing 
clinically expressed AIP may further result in sustained hypertension and impaired renal function 
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(37), while endocrine abnormalities such as glucose intolerance (38) have also been described.  
The course of an acute attack is variable, with some patients experiencing partial or complete 
neurological recovery, while others may be left with long-term motor or sensory sequelae.  
Patients, mostly female, who suffer frequent attacks tend to become increasingly immobilised by 
motor neuropathy.  The outlook for patients suffering from acute attacks has, however, improved 
significantly over the recent past, with the majority of patients with AIP or variegate porphyria 
reporting that they lead normal lives (1).  Despite the apparent increased understanding and 
awareness of acute porphyria, the differential diagnosis of particularly undifferentiated 
neurological presentations can be difficult.  Delayed diagnosis is problematic as it can lead to the 
use of contra-indicated drugs, and delay specific therapy that potentially increases the risk of 
irreversible neurological damage. 
 
It is clear, therefore, that pre-symptomatic diagnosis of AIP would be of great advantage to 
individuals shown to carry a proven disease-causing mutation.  Such studies are essential in the 
management of families, and are best performed using DNA analysis (15).  Appropriate 
counselling can be given as to how to minimise risk of suffering an acute attack and, equally 
importantly, unaffected family members can be reassured as to their non-porphyric status. 
 
Pathophysiology of the Acute Attack 
It is interesting to speculate on the possible mechanisms underlying the neuropathology in acute 
porphyria, and several hypotheses have been proposed.  The two leading hypotheses are 
haem/haemoprotein deficiency in nerve cells and the neurotoxicity of ALA, PBG and/or other 
porphyrin metabolites (39).  If the pathogenesis of AIP was caused by haem deficiency, then it 
would be expected to cause early neurological features, reminiscent of those seen in 
mitochondrial disorders associated with encephalopathies.  Indeed, the white matter 
abnormalities seen in patients with AIP (the homozygous recessive variant) differ from those 
reported in mitochondrial disorders, and muscle mitochondrial respiratory chain enzymes from 
these patients are normal.  Based on magnetic resonance imaging studies, it has been proposed 
that ALA-mediated neurotoxicity appears to be the most likely mechanism causing the 
pathological features of AIP (39).  Brain white matter appears to be selectively affected in AIP, 
and it has been proposed that the homology of ALA with glutamate and aspartate (excitatory 
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neurotransmitters) could affect regions of the brain susceptible to excitotoxicity.  The foetal brain 
may be protected from the toxic effects of haem precursors due to their post-placental clearance 
from circulation by the maternal renal system (39).  Peripheral neurotoxicity induced by ALA 
has been demonstrated to cause de-myelination, most likely as a result of the oxidative properties 
of ALA (40).  Interference by ALA with the action of another neurotransmitter, γ-aminobutyric 
acid, on the basis of structural similarity, has also been suggested and may inhibit presynaptic 
GABA release or act postsynaptically as a partial GABA receptor agonist/antagonist (41).  
Interestingly, administration of ALA to a healthy volunteer did not precipitate acute 
symptoms (5). 
 
The most convincing evidence for the role of haem precursors in acute attacks is the report of a 
19-year-old female, with heterozygous AIP, who underwent an allogeneic liver transplant after 
37 hospital admissions over 29 months.  Her ALA and PBG concentrations normalised within 24 
hours and she had not had any further attacks 1.5 years after transplant (42).  The gene defect 
was corrected in the liver hence the normalisation of precursor levels, but this is clearly not the 
case in other tissues, including the nervous system.  One would expect that if haem deficiency 
was an important component of the pathophysiology of the acute attack, the patient would not 
have such a dramatic resolution of her symptoms.  A functional haem deficiency could still be 
considered, however, based on the elevated plasma levels and brain delivery of tryptophan in the 
rat, as a consequence of reduced activity of hepatic tryptophan pyrrolase, a haem-dependent 
enzyme (43).  Furthermore, gene targeting has produced a mouse model of PBGD deficiency and 
these animals develop a chronic peripheral neuropathy at normal or only slightly elevated levels 
of ALA (44), thus supporting the hypothesis that haem deficiency in murine nervous tissues is 
also involved in the disease pathogenesis. This issue may, however, have finally been put to rest 
by the results of recent domino liver transplantations (45).  Patients with hepatoma, who were 
transplanted with liver from AIP patients, developed acute attacks including symptoms of 
peripheral neuropathy, associated with elevated ALA and PBG excretion.  It is clear that the only 
source of neurotoxin is the liver, establishing that haem deficiency in neuronal tissue plays little 
role in the pathogenesis of acute attacks in porphyria. 
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Precipitating Factors                         
The majority of asymptomatic heterozygotes with a documented HMBS gene defect will remain 
clinically latent for the duration of their lives, although they may exhibit baseline PBG 
concentrations up to 50-fold higher than the upper reference limit (46).  A relatively small 
proportion of individuals with latent or previously clinically expressed AIP, may manifest an 
acute AIP attack after exposure to precipitants which may be endogenous, or exogenous 
environmental factors.  It is generally held that most precipitating factors are related to an 
increase in liver ALAS activity, the rate-limiting enzyme in haem biosynthesis, presumably as a 
consequence of increased hepatic haem demand.  However, increased ALAS activity, in the 
presence of an approximately 50% decrease in PBGD activity, converts the latter enzyme into 
the rate-limiting step, causing the accumulation of ALA and PBG and precipitating an acute 
attack.  Under normal conditions therefore, the demand on the haem biosynthetic pathway is 
below the threshold at which the rate of PBGD activity becomes rate-limiting. 
 
A variety of precipitants may induce an acute attack, and the leading endogenous cause is 
endocrine.  Clinically expressed AIP is rare before puberty and after menopause, and is more 
common in women, especially during the pre-menstrual period.  Naturally occurring sex steroid 
metabolites induce de novo synthesis of hepatic ALAS and increase hepatic cytochromes P-450, 
while synthetic steroids are also known to induce porphyria (1, 5).  Interestingly, and perhaps 
paradoxically, women with AIP fare well during pregnancy despite the large elevations in sex 
steroid concentrations (47), however first time mothers with active acute porphyria appear to 
have elevated risk of perinatal loss (48).  An underestimated precipitating factor is reduced 
caloric intake.  Hepatic haem oxygenase is induced by fasting (49), which results in decreased 
hepatic haem concentrations thereby de-repressing ALAS1.  Also, as discussed previously, a low 
glucose concentration activates PGC-1α which increases ALAS1 expression (10), thereby 
increasing the flux through the haem biosynthetic pathway.  These mechanisms probably account 
for fasting-induced acute attacks in AIP. 
 
One of the primary culprits for precipitating an acute attack is drugs and, indeed, many patients 
do well after a diagnosis of AIP has been made if they avoid harmful drugs.  It is well known, 
however, that induction of ALAS, the rate controlling enzyme of the haem biosynthetic pathway, 
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is crucial to drug porphyrogenicity.  The defective gene in the haem biosynthetic pathway 
becomes rate-limiting, resulting in the accumulation of precursor metabolites.  Indeed, drugs are 
able to induce or suicidally inactivate hepatic cytochrome P-450, an event which is central to this 
process (50).  Many drug safety lists, categorising drugs as safe or unsafe in porphyria, have 
been published including those lists found on our University of Cape Town website 
(http://web.uct.ac.za/depts/porphyria), and perhaps more fully, and certainly the most up to date, 
those lists on the Norwegian (NAPOS) component of the European Porphyria Network website 
(http://www.drugs-porphyria.org). 
 
In addition, a number of other factors such as smoking (51), infections, surgery, inter-current 
illness and alcohol excess are known to contribute to an exacerbation of AIP (1, 5).  An 
intriguing finding is noted in a small study in northern Sweden, where a group of 16 patients 
with AIP subsequently developed type 2 diabetes mellitus.  Of this group 8 had clinically 
manifest AIP but remained free from acute attacks after the onset of diabetes (52).  The 
mechanism of this seemingly protective effect of diabetes is unclear. 
 
Diagnosis 
The signs and symptoms of an acute attack are very non-specific, and a high index of suspicion 
is required, particularly in the context of patients from a non-porphyric background or in 
children.  The abdominal pain of the acute attack can mimic many other often more common 
conditions, and the yield of screening for acute porphyria should be expected to be low. 
 
An acute porphyric attack is associated with the characteristic increases in serum ALA and PBG, 
which are excreted into urine.  The first-line investigation for a patient suspected of suffering 
from an acute attack is, therefore, examining the urine for these precursors (1, 5, 11).  Both 
compounds are excreted in large amounts during acute attacks with a mean PBG excretion of 50-
fold above the reference interval (53).  Although not essential to measure ALA, it can be useful 
to detect autosomal recessive ALA dehydratase porphyria, lead poisoning or tyrosinaemia type 1, 
all of which are associated with depressed ALA dehydratase activity.  About 66% of latent AIP 
carriers show normal urinary PBG excretion while the remainder exhibit slightly increased 
excretion (53).  Patients with clinically expressed AIP excrete variably increased PBG and ALA 
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between attacks but approximately 10% of such patients remain undetected by urinary PBG 
analysis (53).  Uroporphyrin and coproporphyrin are usually only moderately elevated in urine 
during an acute attack, while stool porphyrins are normal or only slightly increased.  Variegate 
porphyria and hereditary coproporphyria, the other two porphyrias associated with the acute 
attack, are associated with much greater increases of stool porphyrins, and may also manifest 
photocutaneous symptoms.  Variegate porphyria can often be identified by the presence of a 
peak at 626nm on plasma fluorescence emission spectroscopy (54), although this peak may shift 
to a slightly shorter wavelength (e.g. 620nm) during the acute attack (UCT Porphyria lab 
experience).  Serial measurements of urinary PBG are a useful reflection of disease activity, and 
are used to evaluate the biochemical response to therapy.  These measurements are particularly 
useful in patients who present late, where clinical improvement, which is often used to gauge 
response to therapy, may be limited.  Urinary PBG is also used in the under-resourced South 
African environment where less hemin may be given, and increasing levels are an early indicator 
of clinical rebound.  Indeed, the index of individuality values for PBG and ALA suggest that 
comparison of repeat samples with the reference change value may be superior to reference 
intervals for clinical interpretation.  A 2-fold increase in PBG will be detected with a probability 
of greater than 80% independent of the baseline concentration, and is of clinical significance 
(46).   
 
The Watson-Schwartz test is a qualitative screening assay for urinary PBG, which produces a 
pink/red chromogen after the addition of Ehrlich’s reagent (para-dimethylaminobenzaldehyde in 
strong acid).  A solvent extraction step is able to separate the chromogen formed by PBG from 
similar chromogens formed by urobilinogen and other interferents.  The draw-backs of this 
method are that it lacks sensitivity, is not quantitative and is prone to positive interference.  For 
this reason a quantitative assay, such as an anion-exchange column method (55) (originally 
described in 56) should be used to verify qualitative results.  
 
Family screening is essential to identify individuals at risk of developing clinically manifest AIP, 
so that adequate precautions can be taken to prevent acute attacks.  The diagnosis of AIP in 
asymptomatic carriers and family members of AIP sufferers cannot be made using the same 
approach as for an acute attack, as haem precursors are often normal.  The diagnosis therefore 
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relies on the demonstration of an approximately 50% reduction in PBGD activity in erythrocytes, 
but low activity does not distinguish between latent gene carriers and clinically manifest AIP.  
Normal erythrocyte PBGD activity also does not exclude AIP in the case of the non-erythroid 
variant, where decreased activity may be demonstrated in cultured fibroblasts or lymphocytes 
(5).  Furthermore, the range of activity of PBGD in erythrocytes of normal individuals is wide, 
and overlaps with that of patients with AIP.  For these reasons, therefore, mutation analysis is 
recommended and often included as a diagnostic modality.   
 
Treatment of the Acute Attack (or AIP)      
Although prompt and successful treatment is the primary focus of a patient suffering from an 
acute porphyric attack and is the primary aim of the attending physician, this review will only 
address general treatment principles.  The first aims should be to identify and remove any 
potential precipitants of an acute attack, particularly drugs, hypocaloric intake and underlying 
infections.  Pain, hypertension and electrolyte disturbances, particularly hyponatraemia, should 
be promptly treated and bedside spirometry should be available to detect early pseudobulbar 
palsy necessitating ventilation.  The use of intra-venous haem arginate preparations to repress 
ALAS1 activity is the most effective way of reducing production of PBG and ALA, and 
represents the treatment of choice (57).  Haem arginate or hemin administration may prevent the 
onset and progression of neuropathy, but will not reverse already established neuropathy (11).  
The biochemical response to haem arginate therapy can be monitored with serial urinary PBG 
measurement but clinical monitoring must also be used as a guide to whether/when repeat haem 
treatments are perhaps necessary.  Prophylactic haem arginate may occasionally be required for 
patients who have severely compromised quality of life due to recurrent acute attacks.  Its use is 
not licensed for this indication, and complications related to iron overload, venous network 
toxicity and difficulty with treatment withdrawal occur (16). 
 
Patients should be counseled about avoidance of precipitants, particularly unsafe drugs, smoking, 
alcohol and the maintenance of a healthy diet while avoiding fasting.  As discussed above, liver 
transplantation has resulted in excellent clinical and biochemical responses, but such treatment 
should be reserved for select patients with the most severe and seemingly intractable forms of 
AIP (58).  An extension of the theme of the restoration of PBGD activity in the liver to cure AIP 
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is the intriguing possibility of liver-specific gene therapy.  A recent report (59) provides evidence 
of liver-directed gene therapy using a liver-specific enhancer and promoter to achieve high levels 
of hepatic PBGD expression in a mouse AIP model.  These mice were protected from 
biochemical induction of acute attacks, and demonstrated significant improvement in neuromotor 
function.  This study provides a rationale for gene therapy in AIP patients with recurrent acute 
attacks.  Indeed a collaborative project, involving seven partners from four European countries, 
aims to develop the clinical use of the orphan drug AAV5-AAT-HMBS for the treatment of AIP 
(http://www.aipgene.org/; last accessed June 2013).  AAV is a replication-incompetent virus that 
has been modified to deliver genes into human cells. AAV5-AAT-HMBS acts by delivering the 
HMBS expression cassette directly into hepatocytes.  The use of gene therapy may not be 
suitable for all patients due to the presence of pre-existing anti-vector antibodies.  A new 
approach, which may be suitable for such patients, is the use of short interfering ribonucleic acid 
(siRNA) to knock down ALAS activity (60).  Using an AIP phenobarbitol induction model, 
siRNA targeting of ALAS may prevent up regulation of the ALAS1 transcript and metabolite 
production during acute attacks, and may herald a promising approach for treatment of AIP. 
 
CONCLUSION 
AIP belongs to a group of porphyric disorders which may present with a characteristic group of 
neurovisceral and motor symptoms.  Unfortunately, although such attacks are acute, they 
potentially leave in their wake long-term neurological sequelae which can be progressive with 
each attack.  It is, therefore, imperative to initiate the formal identification of patients in South 
Africa with clinically expressed AIP at the molecular level, with a view to further screening of 
family members.  This would allow the identification of latent carriers and, importantly, 
education of carriers with respect to precipitants and how best to avoid them so as to minimise 
the risk of provoking an acute attack.  Although only about 10% of AIP heterozygotes ever 
become symptomatic, it is not possible to predict which will manifest clinically.  To this end a 
mutational analysis approach should be used to characterise South African AIP patients and their 
families, initially diagnosed on clinical and biochemical grounds.  This work will also help to 
delineate any possible founder-effect in the South African AIP population, a phenomenon that 
has been observed in other population groups. 
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ABSTRACT 
Aims 
Acute intermittent porphyria (AIP) is a low penetrant autosomal dominant disorder caused by 
mutations in the hydroxymethylbilane synthase (HMBS) gene.  Many mutations in this gene have 
been reported, but knowledge about the spectrum of mutations present in South Africa is limited.  
Identification of such mutations is important so that latent carriers of affected family members 
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can be identified, and counselled to avoid precipitating factors.  This study presents the 
molecular analysis of ten South African AIP patients. 
Methods 
Of the total of 10 patients with clinical and biochemical evidence of AIP, 4 were black, 3 of 
mixed ancestry and 3 Caucasian.  Genomic DNA was isolated from affected probands and 
family members of one proband, and the HMBS gene amplified by PCR and mutations 
characterised by direct sequencing. 
Results 
Four new mutations, a missense p.Lys98Glu; a frameshift mutation, p.Asp230Asp fs*19 and two 
splice site mutations, c.422+3_6delAAGT and c.161-1 G>A, were detected in the South African 
probands.  Three previously described mutations (p.Arg149X, p.Arg116Trp and p.Trp283X) 
were found, while in two patients no mutations were revealed.  Of the latter two, one is deceased 
and the other demonstrated HMBS enzyme activity approximately 50% of normal controls.  
Mutation analysis of 5 offspring of one of the probands carrying the p.Trp283X mutation, 
revealed 2 asymptomatic carriers. 
Conclusion 
This study comprises the most recent and comprehensive characterisation of mutations in the 
HMBS gene of AIP patients in South Africa.  Four of the mutations were novel, and three have 
been previously reported.  One of these mutations, found in a patient of mixed ancestry, probably 
originated in The Netherlands, where a founder population exists. 
 
BACKGROUND 
AIP (MIM # 176000) is an autosomal dominant disorder of haem biosynthesis caused by a 
partial deficiency of HMBS or porphobilinogen deaminase (EC 2.5.1.61).  This enzyme catalyses 
the head-to-tail condensation of four molecules of porphobilibogen (PBG) to form 
hydroxymethylbilane.1  In AIP, porphyrins and their precursors, PBG and 5-aminolaevulinic 
acid, are produced in excess and are excreted in urine and stool for many years after an acute 
attack.2  Biochemical diagnosis of AIP is based the measurement of these urinary precursors, the 
presence of a plasma fluorescence peak at 619nm (with UV excitation around 400 nm) and the 
determination of erythrocyte HMBS activity.  Molecular analysis of the HMBS gene is not 
	   53	  
required to make a diagnosis of AIP, but is essential and worthwhile for presymptomatic 
diagnosis.  A great proportion of patients remain clinically asymptomatic throughout life and are 
thus potentially at risk of an acute attack.  There is, thus, a need for genetic screening of family 
members potentially at risk. 
 
Clinically, AIP manifests as intermittent attacks of neurovisceral dysfunction, which can be 
precipitated by various factors such as drugs, hormones and alcohol.1,4  Indeed, 80-90% of 
patients who inherit a defective AIP gene remain clinically latent for life,3 reflecting the poor 
penetrance of this disease.  A recent European study revealed an incidence of symptomatic AIP 
of 0.13 per year per million population.  In northern Sweden, due to a founder effect, the 
incidence is as high as 0.51 per year per million.5 
 
The human HMBS gene consists of 15 exons spanning over 10kb of genomic DNA, and is 
located at chromosome 11q23.3.  Located in the 5’ flanking region and in intron 1 are two 
distinct promoters which generate the housekeeping (containing exons 1 and 3-15) and erythroid-
specific (containing exons 2-15) transcripts by alternative splicing of exon 1 and 2.6  Three 
hundred and ninety mutations in the HMBS gene have been reported in the Human Genome 
Mutation Database (http://www.hgmd.org) including those in several small studies in South 
Africa.7-9  To date, ten patients in South Africa have had a diagnosis of AIP confirmed at the 
gene level, of whom four carry the p.Arg116Trp mutation, described as occurring commonly in 
the Netherlands, due to a founder effect.10  The ancestry of three of these patients suggests a 
mixture of Malay, European and Khoi blood.  The European component may well be Dutch, 
thereby explaining the presence of this mutation in these apparently unrelated patients.  The 
present study expands the cohort of South African patients with a molecular diagnosis of AIP, 
revealing four novel mutations, and opening the way for family studies. 
 
MATERIALS AND METHODS 
Selection of study cohort 
The University of Cape Town Lennox-Eales Porphyria Laboratory is a national referral centre 
for porphyria diagnosis and management. A total of 29 patients with a clinical and biochemical 
(not shown) diagnosis of AIP were designated as potential participants in this study. Of these, 10 
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patients were ultimately recruited and of these, 6 previously had DNA stored for further study, 
and 4 were newly recruited. The remainder of the patients were not traceable. Of the 10 
participants, 4 were black, 3 of mixed-race and 3 of Caucasian origin. Two of the Caucasians 
were siblings, and 5 offspring (all asymptomatic) of one of the siblings were screened for 
mutations.  Informed consent was obtained from the 3 newly recruited patients, while analysis of 
the HMBS gene of the other 7 participants was considered imperative for confirmation of 
diagnosis. Ethical approval for this study was obtained from the Health Sciences Faculty 
Research Ethics Committee (HREC/REF: 324/2010), University of Cape Town, South Africa. 
No member of this cohort is known to be related to South African patients previously 
investigated7-9 for HMBS mutations. 
 
Molecular analysis 
Genomic DNA was isolated from 2.5ml whole blood, using the Wizard Genomic DNA 
Purification kit (Promega, Madison, USA) as per the manufacturer’s protocol.  PCR 
amplification of all 15 exons and flanking intronic sequences was carried out using primers, 
designed using Primer Designer version 2.0, as detailed in Table 1. PCR products spanning all 
exons of the entire HMBS gene were subjected to direct sequencing, to determine the precise 
sequence variations.  PCR products were purified for sequence analysis using the GFX PCR 
DNA and Gel Band purification kit (GE Healthcare, Buckinghamshire, UK).  In most cases 
purified samples were then sequenced in both forward and reverse directions on an ABI 3130 XL 
DNA automatic sequencer using a Big Dye terminator cycle sequencing kit, by the Department 
of Genetics, University of Stellenbosch, Stellenbosch, South Africa.  Sequence data were 
collected and analysed using BioEdit Sequence Alignment Editor, Version 5.0.9.1 (Tom Hall, 
North Carolina State University, USA). Sequences in BioEdit were aligned with Genbank data 
(http://www.NCBI.nlm.nih.gov) using ClustalW (http://dot.imgen.bcm.tmc.edu:9331/ multi-
align/Options/clustalw.html). 
 
Restriction Enzyme Digestion 
Sequence analysis revealed 4 unpublished mutations (see Results). The absence of these 
mutations was confirmed in at least 50 race-matched control DNA specimens by restriction 
enzyme digest analysis (mutation: c.292A>G and enzyme: Sty1; mutation: c.689_690delAC and 
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enzyme: BstY1; mutation: c.422 + 3_6delAAGT and enzyme: XcmI; mutation c.161-1G>A and 
enzyme DdeI).  The DNA of family members of 2 related probands was also interrogated with 
restriction analysis (mutation: c.848G>A; enzyme: XbaI).  Restriction enzyme maps for wild 
type and polymorphic DNA fragments were constructed using Webcutter 2.0 (copyright 1997, 
Max Heiman). 
 
HMBS Enzyme Assay 
HMBS activity was determined according to Piepkorn et al.11  Whole blood (50µl) was 
incubated with haemolysing reagent (0.2% Triton X-100, 1mM dithiothreitol and Zn ions in the 
form of ZnSO4.7H2O; 1ml) for 30min at 37°C.  Two and a half ml of 10% trichloroacetic acid 
was added to one reaction mixture to create a blank, and 4mM ALA in phosphate buffer, pH7.5 
(1ml), added to the blank and test specimens and incubated at 37°C for 1h.  Ten % 
trichloroacetic acid (2.5ml) was added to the test specimens, the samples allowed to stand in the 
dark for 30min, centrifuged and the fluorescence (relative fluorescence units) of the standards 
(coproporphyrin standard was diluted to 50, 100 and 200ng/ml with 1.5mM HCl), blank and test 
specimens recorded at an excitation wavelength of 405nm and excitation wavelength of 595nm.  
HMBS enzyme activity was calculated in nmol.h.-1ml-1 red blood cells (haematocrit). 
 
RESULTS 
Sequence analysis of the HMBS gene in 10 patients revealed 7 mutations, 4 of which were novel 
(Table 2).  A pair of siblings elaborated the same mutation, while in 2 patients no mutation was 
found.  The p.Arg149X mutation in exon 9 creates a premature stop codon and was identified in 
a black patient, and has previously been found in Finnish families.12  Similarly the p.Arg116Trp 
mutation in exon 8 identified in a patient of mixed race, was revealed in the same Finnish study12 
but has also been commonly found in the Dutch AIP population.10  Two Caucasian siblings (a 
male and female) were identified with the p.Trp283X mutation13 in exon 14, and restriction 
analysis (using the restriction enzyme XbaI, results not shown) of DNA obtained from the 
offspring of the male sibling showed that 2 of 5 children had inherited this mutation (Table 2), 
but neither children have had symptoms consistent with AIP.  Two patients with a biochemical 
diagnosis of AIP were found not to harbour exonic HMBS mutations in the exons and flanking 
regions interrogated.  One of these patients, a female of mixed ancestry, deceased at the age of 
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14 years. HMBS enzyme analysis of red blood cells derived from the other patient, a female of 
black ancestry, showed activity of 13.8nmol/h/ml red blood cells, 49.2% of normal control 
activity (average activity of 3 controls: 28.0nmol/h/ml).  This is consistent with the expected 
50% decreased in enzyme activity in patients with AIP. 
 
The four novel mutations included a missense mutation (p.Lys98Glu), two splice site mutations 
(c.422+3_6delAAGT and c.161-1 G>A) and a frameshift mutation (p.Asp230Asp fs*19).  The 
p.Lys98Glu mutation resulted from an A-to-G transition in exon 7 predicting the substitution of 
positively charged lysine for a negatively charged glutamic acid.  The c.422+3_6delAAGT 
mutation in intron 8 and c.161-1 G>A mutation in intron 4 generate a putative donor and 
acceptor splice site mutation, respectively.  The deletion in exon 12 of the second and third bases 
of codon GAC (aspartic acid) generates a new codon GAT, also representing aspartic acid.  
Further, a frameshift occurs which predicts substitution of 19 amino acids in codons 230 to 248 
and chain termination at codon 249 (230DILDLVGVLHDPETLLRCI to 
230DLGSGGCAARSRDSASLHRX), thereby deleting the last 111 amino acids of the 361 
amino acid HMBS enzyme.  None of the changes observed in patients with unpublished 
mutations were detected in the control groups. 
 
DISCUSSION 
This report reflects the most current interrogation of HMBS mutations in AIP patients in South 
Africa.  Regrettably this cohort is incomplete, the task being complicated by difficulties with 
tracing and following up patients in a fragmented health care system and a finite time period for 
this study.  Nevertheless, molecular investigation of AIP patients is an important step in the 
management of families, where screening is essential to identify those with latent disease so as to 
prevent acute attacks.3,14  The sensitivity for mutation detection determined by sequencing is 
95%,15 and increases to 98.1% if gene dosage analysis is included.16  This provides greater 
diagnostic accuracy than erythrocyte HMBS activity analysis.3    
 
This study identified a total of 7 mutations in the 10 patients screened.  It is well known that 
most AIP mutations are private and limited to the families in which they arise.  This is supported 
by the fact that, to date, 390 mutations have been identified in the HMBS gene in AIP.  Three of 
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the mutations found have been previously described.  The p.Arg149X mutation creates a 
premature stop codon and was first identified in two Finnish families,12 but in this study it was 
identified in a black male.  Indeed, this mutation has also been detected in Spanish probands17 
and occurs at CpG dinucleotides, which are known mutation hotspots.  The p.Arg116Trp 
mutation was found in a patient of mixed ancestry, and the same mutation was revealed in a 
previous study of 3 South African mixed ancestry patients.8  A relatively high frequency of this 
mutation (19/80 families) has been found in the Dutch AIP population and a distinctive 
haplotype was found to segregate with the p.Arg116Trp mutation in this population.10  This 
suggests a founder effect, and as the ancestry of all South African patients with this mutation is  
mixed, it is likely that the mutation is of Dutch origin, considering the Dutch colonial history of 
South Africa.  A further founder mutation is p.Trp283X, found in 56% of AIP patients in 
Switzerland and has thus the highest prevalence of any single HMBS gene mutation in an AIP 
population.18  The two siblings found to harbour this mutation are Caucasian, but are not known 
to have Swiss ancestry as far as could be determined, and haplotype studies would be required to 
establish if their mutation is linked to the founder mutation.  Indeed, the utility of a molecular 
diagnosis of asymptomatic family members is highlighted by the revelation that 2 of 5 offspring 
of one of the siblings were also found to carry the mutation.  This allows for appropriate 
counselling of the parents and children, both those carrying the mutation and those found to be 
mutation free.   
 
Two patients with clinical and biochemical evidence (results not shown) of AIP were shown not 
to have coding region mutations or mutations in flanking regions.  One of these patients 
presented peri-pubertally at the age of 11 years, but demised 3 years later.  The other patient is 
still being followed up, and erythrocyte HMBS activity was shown to be decreased by about 
50%, consistent with AIP.  In such patients, where no mutations can be found, quantitative PCR 
for gene dosage analysis is necessary to exclude large deletions and insertions or functional 
intronic mutations caused by nonsense mediated decay.3  A recent report further suggests mRNA 
analysis to exclude pseudoexon inclusion as a cause of AIP in mutation negative patients.19 
 
This study revealed four novel mutations.  Lysine at position 98 has previously been 
demonstrated to mutate to arginine12 (p.Lys98Arg) but we reveal a change to glutamic acid 
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(p.Lys98Glu).  This lysine moiety is located within the active site cleft and in close proximity to 
the dipyromethane cofactor, and is probably critical for substrate docking and catalysis.20  
Bacterial expression of the wild-type and the p.Lys98Glu mutated HMBS proteins by workers in 
our laboratory (Pienaar pers.com.), facilitated kinetic analysis which revealed a KM for the 
mutated enzyme approximately double that of the wild-type enzyme.  Furthermore enzyme 
efficiency, expressed as Kcat/KM, was almost negligible.  It was also shown that the p.Lys98Arg 
mutant lost its ability to bind the dipyromethane co-factor, which was not the case for the 
p.Lys98Glu mutant.  This mutant replaces a positively charged amino acid with one which is 
negative, suggesting that charge is not important for co-factor binding, whereas the more bulky 
arginine moiety in the p.Lys98Arg mutant appears to disrupt the binding of the co-factor.  
Indeed, it appears that charge is important for the ability of the enzyme to interact with its 
substrate, as reflected by the loss of substrate affinity in the p.Lys98Glu mutant. 
 
Two intronic lesions were detected, and are hypothesised to adversely influence splicing.  A 
mutation in the same position as c.161-1G>A in intron 4 has been described, except that a G to C 
transition occurs.21  The p.Asp230Asp fs*19 mutation in exon 12 causes a frameshift, resulting 
in a truncated protein most likely with compromised enzyme activity.  During the preparation of 
this manuscript, a further HMBS mutation was characterised in a Caucasian patient with a 
biochemical diagnosis of AIP (Pienaar pers. com.).  In exon 12, c.771insT introduces a stop 
codon 33 codons downstream, thereby producing a truncated protein.  This mutation has 
previously been described in South Africa.8 
 
 There is a dearth of information on AIP in black and mixed ancestry patients and, in particular, 
the scope of HMBS mutations is almost unknown in the African context.  A study of seven West 
and North African and Afro-Caribbean AIP patients characterised six different mutations, four of 
which were novel.22  In this study, three of the four novel mutations were found in black or 
mixed ancestry patients.  Although studies are limited, it appears that AIP is not uncommon in 
blacks, and the disease-causing mutations are heterogeneous except for, perhaps, p.Arg116Trp 
which may be of Dutch origin.  Furthermore, the spectrum of mutations demonstrated in black 
patients appears to be different to those observed in the white population.  From the data in this 
study, it is not possible to make inferences about the prevalence of HMBS mutations in South 
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Africa.  This could be achieved by a larger, directed prospective study of AIP patients, using this 
study as a starting point.  Further studies are required to delineate the scope of mutations in other 
regions of Africa, and the continuing emergence of novel mutations and the heterogeneity of 
mutations demonstrates the usefulness of prior characterisation of HMBS mutations in newly 
diagnosed patients, to allow detection of relatives with latent AIP. 
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Table 1: Characteristics of the HMBS gene primers used 
Amplicon Primer pair Size 
(bp) 
Product 
size (bp) 
Tm 
(°C) 
Sequence 
Exon 1 HMBS F1 20 342 58 5’ggtccactgtcgcaatgttc3’ 
 HMBS R1 20   5’tagacgactgaggatggcaa3’ 
Exon 2-3 HMBS 2F 19 902 58 5’gcctcttgctggagaaggt3’ 
 HMBS 3R 19   5’agccacggctcagactctt3’ 
Exon 4-6 HMBS 4F 19 814 58 5’gcctaacctgtgacagtct3’ 
 HMBS 6R 19   5’ccagcagcctatctgacac3’ 
Exon 7-9 HMBS 7F 19 854 58 5’aggctccaccactgaagta3’ 
 HMBS 9R 19   5’tgagtggacggatgagtgc3’ 
Exon 10 HMBS 10F 19 598 58 5’agacagactcaggcagagg3’ 
 HMBS 10R 19   5’ccagcctacggtgttagag3’ 
Exon 11-12 HMBS 11F 19 787 54  5’ctctaacaccgtaggctgg3’ 
 HMBS 12R 20   5’acagacctgaggacatcact3’ 
Exon13-15 HMBS 13F 20 781 58 5’atgtcctcaggtctgtggtc3’ 
 HMBS 15R 20   5’cacatactgaggaggcaagg3’ 
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Table 2: Mutation spectrum in the HMBS gene in South African patients with AIP 
Patient Gender/Race 
Ma=male 
F=female 
B=Black 
C=Caucasian 
Mi=mixed 
ancestry 
Location 
of 
mutation 
 
Molecular 
defect 
Predicted 
protein 
product 
Enzyme 
activityd 
(nmol/h/ml red 
blood cells) 
1 Ma/B Exon 9 c.445C>T p.Arg149X N/De 
2 F/Mi Exon 8 c.346C>T p.Arg116Trp N/D  
3 Ma/Ca Exon 14 c.848G>A p.Trp283X N/D  
4 F/Ca Exon 14 c.848G>A p.Trp283X N/D  
5 Ma/Cb Exon 14 c.848G>A p.Trp283X N/D  
6 F/Cb Exon 14 c.848G>A p.Trp283X N/D 
7 F/Mi No 
mutation 
found 
  N/D  
(patient 
deceased) 
8 F/B No 
mutation 
found 
  13.8 
9 Ma/C Exon 7 c.292A>G p.Lys98Gluc N/D  
10 F/B Intron 8 c.422+3_6d
elAAGT 
Splicing 
aberrationc 
N/D 
11 Ma/Mi Exon 12 c.689_690 
delAC 
p.Asp230Asp 
fs*19c 
N/D 
12 F/B Intron 4 c.161-1 
G>A 
Splicing 
aberrationc 
N/D 
aSiblings 
bSiblings, and offspring of patient 3 
cNovel mutations 
dPBGD enzyme activity range: 24.0-54.0nmol/h/ml red blood cells11 
eN/D: not determined 
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statements to the legends. 
 
Tables 
Tables should be submitted in the same format as your article (Word) and not another format embedded into the 
document. They should appear where the table should be cited, cited in the main text and in numerical order. Please 
note: we cannot accept tables as Excel files within the manuscript.  
If your table(s) is/are in Excel, copy and paste them into the manuscript file.  
Tables should be self-explanatory and the data they contain must not be duplicated in the text or figures - we will 
request that any tables that are longer/larger than 2 pages be uploaded as web only data. 
 
References 
Authors are responsible for the accuracy of cited references: these should be checked against the original documents 
before the paper is submitted. It is vital that the references are styled correctly so that they may be hyperlinked.  
 
Citing in the text  
References must be numbered sequentially as they appear in the text. References cited in figures or tables (or in 
their legends and footnotes) should be numbered according to the place in the text where that table or figure is first 
cited. Reference numbers in the text must be inserted immediately after punctuation (with no word spacing)—for 
example,[6] not [6].  
Where more than one reference is cited, separate by a comma—for example, [1, 4, 39]. For sequences of 
consecutive numbers, give the first and last number of the sequence separated by a hyphen—for example, [22-25]. 
References provided in this format are translated during the production process to superscript type, which act as 
hyperlinks from the text to the quoted references in electronic forms of the article. 
Please note, if your references are not cited in order your article will be returned to you before acceptance for correct 
ordering. 
 
Preparing the reference list  
References must be double spaced (numbered consecutively in the order in which they are mentioned in the text) in 
the [slightly modified] Vancouver style (see example below). Only papers published or in press should be included in 
the reference list. (Personal communications or unpublished data must be cited in parentheses in the text with the 
name(s) of the source(s) and the year. Authors should get permission from the source to cite unpublished data.).  
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References must follow the [slightly modified] Vancouver style:  
12 Surname AB, Surname CD. Article title. Journal abbreviation Year;Vol:Start page–End page.  
Use one space only between words up to the year and then no spaces. The journal title should be in italic and 
abbreviated according to the style of Medline. If the journal is not listed in Medline then it should be written out in full.  
Check journal abbreviations using PubMed.  
List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and add et al. (The exception 
is the Journal of Medical Genetics, which lists all authors.) 
Example references:  
Journal article 
13 Koziol-Mclain J, Brand D, Morgan D, et al. Measuring injury risk factors: question reliability in a statewide sample. 
Inj Prev 2000;6:148–50.  
Chapter in book 
14 Nagin D. General deterrence: a review of the empirical evidence. In: Blumstein A, Cohen J, Nagin D, eds. 
Deterrence and Incapacitation: Estimating the Effects of Criminal Sanctions on Crime Rates. Washington, DC: 
National Academy of Sciences 1978:95–139.  
Book 
15 Howland J. Preventing Automobile Injury: New Findings From Evaluative Research. Dover, MA: Auburn House 
Publishing Company 1988:163–96.  
Abstract/supplement 
16 Roxburgh J, Cooke RA, Deverall P, et al. Haemodynamic function of the carbomedics bileaflet prosthesis 
[abstract]. Br Heart J 1995;73(Suppl 2):P37.  
 
Electronic citations 
Websites are referenced with their URL and access date, and as much other information as is available. Access date 
is important as websites can be updated and URLs change. The "date accessed" can be later than the acceptance 
date of the paper, and it can be just the month accessed. See the 9th edition of the AMA Manual of Style for further 
examples. 
 
Electronic journal articles 
Morse SS. Factors in the emergency of infectious diseases. Emerg Infect Dis 1995 Jan-Mar;1(1). 
www.cdc.gov/nciod/EID/vol1no1/morse.htm (accessed 5 Jun 1998). 
 
Electronic letters 
Bloggs J. Title of letter. Journal name Online [eLetter] Date of publication. url 
eg: Krishnamoorthy KM, Dash PK. Novel approach to transseptal puncture. Heart Online [eLetter] 18 September 
2001. http://heart.bmj.com/cgi/eletters/86/5/e11#EL1 
Check your citation information using PubMed. 
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Digital Object Identifiers (DOIs)  
DOIs are a unique string created to identify a piece of intellectual property in an online environment; particularly 
useful for articles which have been published online before appearing in print (and therefore the article has not yet 
been assigned the traditional volume, issue and page number reference). The DOI is a permanent identifier of all 
versions of an article, whether raw manuscript or edited proof, online or in print. Thus the DOI should ideally be 
included in the citation even if you want to cite a print version of an article.  
 
How to cite articles before they have appeared in print 
1. Alwick K, Vronken M, de Mos T, et al. Cardiac risk factors: prospective cohort study. Ann Rheum Dis Published 
Online First: 5 February 2004. doi:10.1136/ard.2003.001234  
 
How to cite articles once they have appeared in print 
1. Vole P, Smith H, Brown N, et al. Treatments for malaria: randomised controlled trial. Ann Rheum Dis 
2003;327:765–8 doi:10.1136/ard.2003.001234 [published Online First: 5 February 2002.  
More comprehensive guidance about DOIs.  
 
PLEASE NOTE: RESPONSIBILITY FOR THE ACCURACY AND COMPLETENESS OF REFERENCES RESTS 
ENTIRELY WITH THE AUTHORS. 
 
Supplementary material  
You may submit supplementary material which may support the submission and review of your article. This could 
include papers in press elsewhere, published articles, appendices, video clips (please see Multimedia 
files instructions), etc. 
All supplementary material files should be uploaded using the File Designation: Supplementary material. 
 
Online only material  
Additional figures and tables, methodology, references, raw data, etc may be published online only to link with the 
printed article. If your paper exceeds the word count you should consider if any of the article could be published 
online only as a "data supplement". These files will not be copyedited or typeset.  
All Appendices should be considered Online only material. 
All data supplement files should be uploaded using the File Designation: Web Only files.  
Please ensure any data supplement files are cited within the text of the article. 
 
Multimedia files 
You may submit video and other files to enhance your article (video files should be supplied as .avi, .wmv, .mov .mp4 
or .H264). When submitting video files, ensure you upload them using the File Designation “Video Files”.
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University of Cape Town Dissertation Guidelines 
 
 
MINIMUM REQUIREMENTS FOR DISSERTATIONS FOR MMED AND MPHIL FOR 
SUBSPECIALITIES DEGREES 
Following extensive discussion with Heads of Divisions, Dr S Kalula and Prof S Kidson 
recommend the following minimum criteria for dissertations for MMed and MPhil 
(subspeciality) degrees: 
The MMed minor dissertation (or the MPhil dissertation in the case of subspecialities) is one of 
three examination components of the MMed/MPhil degree. This minor dissertation carries one 
third of the weight of a full master’s dissertation in terms of its credit weighting. The dissertation 
must be a study containing the results of an analytical, quantitative, or epidemiological study 
carried out by the candidate (for certain disciplines, the candidate may chose instead to do a 
qualitative study, an audit cycle or a formal systemic review). A case report is not acceptable for 
the dissertation. 
 
The dissertation must be the result of independent work of the candidate conducted under the 
guidance and direction of a supervisor(s) and should demonstrate evidence of an ability to 
undertake research, to adequately interpret results and to comprehensively and critically review 
the relevant literature. Although the findings of the research need not necessarily be original, 
they must be seen to advance scientific understanding.  The topic and scope of research will 
depend on the particular disciplines and must be agreed upon in consultation with the 
supervisor(s). 
 
Research Protocol 
Candidates intending to register for the MMed/MPhil Part III are required to submit a full 
research protocol for approval to their respective Departmental Research Committee (DRC). The 
candidate must also obtain FHS UCT Ethics approval prior to conducting their research. This full 
research protocol (together with a copy of the ethics approval letter) must be submitted to the 
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postgraduate administration for approval by the Board of the Faculty of Health Sciences, prior to 
commencement of the research. For most disciplines, submission of the research protocol should 
be made no later than the end of year 2.  The research protocol should outline the scope and 
content of the dissertation and must include the title of the proposed dissertation, name of the 
supervisor(s) and their brief curriculum vitae. 
 
Submission of Dissertations 
On completion, the dissertation should be submitted to the Faculty Postgraduate Officer.  The 
candidate should inform the Faculty Officer one month in advance of the intention to submit. 
Submission deadlines: 
 1. February 17th for June graduation 
 2. August 15th for December graduation 
 
Supervisors will be requested by the Faculty Postgraduate Officer to submit a letter supporting 
submission. This letter should be supplied by the primary supervisor. If this supervisor is 
external, the internal supervisor must be kept informed at every stage of the process. Specific 
submission requirements may be set by individual disciplines. 
 
Note on fees: To avoid attracting fees, dissertations need to be submitted before the beginning of 
the first quarter (first day of academic year), and before the start of the second semester (mid 
July) to qualify for a 50% fee rebate. 
 
Supervisors 
One cannot overemphasize the importance of identifying a dissertation supervisor as early as 
possible. The supervisor should be an individual who can relate to the candidate’s research 
project, be available for frequent and regular discussion and advice, and someone with whom the 
candidate can develop a good working relationship. Where specialised equipment and/or 
laboratory work is required for the study, the supervisor should assist in facilitating such access 
to such facilities. Supervisors may assist candidates in developing scientific communication 
skills but they are not required to do detailed editing or correction of spelling, grammar, or style. 
They may refer candidates to the UCT Writing Centre for this purpose. 
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The primary supervisor may be based outside the candidate’s home department, faculty or 
university. In such a case, an internal (or secondary) supervisor will be required in addition to the 
primary supervisor, to serve as a guide and link to discipline-specific procedures. Primary 
supervisors retain responsibilities to the candidate and the university until the dissertation 
process is complete. 
 
Please note: in order to assist a candidate with a master’s research topic the supervisor needs to 
hold a master’s degree or higher, or have relevant research experience. If the primary supervisor 
does not hold a higher degree or equivalent (such as a Fellowship of The College of Medicine of 
South Africa), then a secondary supervisor who has a higher degree will need to be appointed in 
addition to the primary supervisor. 
 
Candidates are strongly encouraged to publish the study with the supervisor(s) as co-author(s). 
This may require work beyond the graduation date. Such arrangements should be discussed and 
documented in advance. 
 
The Dissertation 
Submission of the dissertation should satisfy the following criteria: 
1. The title page should contain the candidate’s name, dissertation title and the name of 
the university. It must also state the degree, e.g. Master of Medicine (MMed) in Public 
Health Medicine, Occupational Medicine, Family Medicine, Surgery, etc. The title page 
should also include a statement to the effect that the research report is based on 
independent work performed by the candidate and that neither the whole work nor any 
part of it has been, is being, or is to be submitted for another degree to any other 
university. It must also state that this work has not been published prior to registration 
for the abovementioned degree. 
2. The body of the dissertation, which must be structured in 4 parts, should include the 
following: 
Part A: The protocol (as approved by the Departmental Research Committee and 
Faculty Research Ethics Committee). The protocol should not exceed 4000 words. 
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 Part B: A structured literature review appropriate to the subject matter and methods of 
the dissertation. The literature review must, amongst other things, show that the student 
is sufficiently acquainted with the relevant literature and is able to perform a critical 
appraisal and, if appropriate for the topic, show a good understanding of evidence-
based medicine. 
The review should be between 3 000 and 4 000 words. 
A suggested structure for the literature review is as follows: 
 a)  Objectives of literature review 
 b)  Literature search strategy, including inclusion and exclusion criteria 
c)  Quality criteria - some leeway will be allowed here, as candidates will vary in 
their ability to appraise studies. This will also vary with the nature of the 
dissertation 
 d)  Summary or interpretation of literature 
 e)  Identification of gaps or needs for further research 
f)  References (which will overlap with but will not be the same lists as in the 
journal article and protocol) 
Part C: The results of the study must be presented in the form of a manuscript of an 
article for a named peer reviewed journal, meeting all the requirements set out in the 
“Instructions for Authors” of that journal, including the word count and referencing 
style. (Unless specially motivated, the journal chosen will need to allow for at least 
3000 words excluding abstract, tables, figures and references). The “Instructions to 
Authors” of the journal must be appended. The journal chosen for publication must be 
appropriate to the subject matter of the dissertation and accredited by the Department of 
Education or listed in the citation index of the Institute for Scientific Information (ISI). 
Important note:  the candidate need not have submitted the article, not is the acceptance 
of the article and requirement for passing the degree. The norm of practise is to publish 
the study with the supervisor(s) as co-author(s) and candidates are strongly encouraged 
to submit their manuscript either before or after examination of the mini-dissertation.	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Part D: All supporting documents including: 
•   Questionnaire/data capture instrument 
•   Consent forms and any related participant information sheets 
•   Technical appendices, including, if considered necessary, any additional tables 
not included in the main manuscript for the examiner to have available. These 
should be accompanied by a brief narrative 
•   Official Ethics approval letter from the Faculty Research Ethics Committee 
3.  The article does not have to be submitted to the journal in order to meet academic 	  	  	  	  	  	  	  	  
requirements. 
4.  A candidate must submit 2 copies of the dissertation in temporary binding, and an 
electronic copy on compact disc in a universally readable format (e.g. pdf). 
 
Examiners 
The full dissertation will be submitted for examination through the Postgraduate office of our 
Faculty to two external examiners (nominated by the supervisors and HOD).Three examiners 
will be nominated, two of which are invited to examine, and one held as an alternate. All 
examiners must be external to UCT. These nominations are circulated to the Faculty Dissertation 
Committee. It is the supervisor’s (or co-supervisor’s) responsibility to submit names of potential 
examiners to the Faculty Officer when the candidate is ready to submit. The examiners will be 
well briefed regarding the specific requirements and criteria for submission and examination of 
the mini-dissertation. Such criteria will clearly explain the difference between the mini-
dissertation and a Master’s degree by dissertation alone. Details required for each examiner are: 
academic qualifications, postal and/or physical address, telephone and fax numbers and e-mail 
address, and one paragraph description of their standing in the relevant field (drawn from their 
CV if need be). The candidate may not be informed of the identity of the examiners. After the 
outcome of the mini-dissertation has been finalised, the examiners’ identities are made known if 
the examiners have indicated that they do not object to this. 
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Patient Information and Consent Forms 
 
 
PATIENT INFORMATION (English) 
 
ACUTE INTERMITTENT PORPHYRIA 
Introduction 
The porphyrias are a group of genetic diseases in which the haem pathway is disturbed, 
and are reasonably common in South Africa.  This occurs in the liver in some forms of 
porphyria, and in the red blood cells in others. These are not liver or blood diseases and 
these organs function normally. Large amount of substances called porphyrins 
accumulate in the body and this may cause two problems- abnormal sensitivity of the 
skin to sunlight, and a complication called the acute attack. 
Acute intermittent porphyria (AIP) is not a common form of porphyria in South Africa. 
People with AIP develop only one complication of the disease viz. the acute attack (see 
below) Many people with AIP never have any problems and they are referred to as 
silent carriers of the disease. They remain susceptible to an acute attack and should 
take the necessary precautions detailed in our porphyria information booklet  
 
Inheritance of AIP 
AIP is inherited as an autosomal dominant condition. This means that the disease is 
transmitted from one generation to the next, with each child (irrespective of sex) having 
a 50% chance of inheriting the defective gene. However, when a defective gene is 
inherited the person quite commonly does not show the disease at all. In other words, 
one might inherit the disease without showing any sign of it. They may, however, pass 
the mutation on to their children. 
	   83	  
We suspect that there are many different mutations in South African patients with AIP 
(the 4 mutations identified to date are different). This means that the various families are 
not related to one another, and it is chance that they have developed the disease. 
 
Clinical manifestations: 
Patients with AIP do not develop skin disease. This means that the skin is not 
particularly susceptible to exposure to the sun, i.e. is not more so than an individual 
without the disease. 
They are, however, susceptible to an acute attack. A few particularly unfortunate 
patients suffer attacks at short intervals. These patients require specialised treatment 
and their doctors are advised to contact our centre for help and advice 
(www.porphyria.uct.ac.za). In the case of a clinical emergency contact Groote Schuur 
Hospital (021 404 9111) and ask for the Liver registrar/ consultant on duty. However, 
many patients who inherit a mutation never have any problems (silent carriers). 
 
Making a diagnosis of AIP 
As AIP is not common in South Africa (it is much less common than variegate 
porphyria) it is often missed or misdiagnosed. 
To confirm a diagnosis of AIP the relevant tests must be performed in a reliable 
laboratory. In those families in whom the mutation is not known AIP will be diagnosed 
by routine tests of urine and stool and blood from puberty to 22 years (usually manifests 
in this time period), the interpretation being assisted by clinical and family information. 
DNA testing is not routinely available for AIP. However, once a family’s mutation has 
been identified, other family members can be tested at any age. 
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Precaution for individuals with AIP 
Avoid the acute attack. Avoid all medication that is dangerous in porphyia (see 
booklet). Wear a medic alert bracelet stating that you are porphyric. Inform your doctor, 
dentist and pharmacist that you have porphyria to avoid being given unsafe medicines. 
Advise all blood relatives to be tested as they may carry the mutation and develop 
symptoms in the future. 
 
What is an acute attack? 
Patients with AIP are always at risk of an acute attack of porphyria. This may be very 
dangerous thus it is important that they understand how they can prevent such an 
attack. The acute attack occurs when the level of porphyrin precursors (ALA and PBG) 
reach very high levels-far higher than in porphyria. Full details of the acute attack and 
how to avoid one are described in our porphyria booklet. 
 
This study 
This study is to identify the DNA mutation that you have which is causing the AIP. You 
will be required to have blood drawn from you (2x 4.5ml). The DNA will be extracted 
from the blood and analysed to identify the exact mutation. A screening test will then be 
set up to enable easy testing of other members of your family. This is important as 
unidentified family members are at risk of an acute attack. Once the mutation has been 
identified and providing you wish to know, you will be informed of the result and genetic 
counseling made available to you. 
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PATIENT INFORMATION (AFRIKAANS) 
 
AKUUT-INTERMITTERENDE PORFIRIE 
Inleiding 
Die porfirieë is 'n groep genetiese siektes waarin die metabolisme van heem versteur is, 
en is redelik algemeen in Suid-Afrika. Sommige vorms van porfirie kom in die lewer voor 
en ander in die rooibloedselle. Porfirie is nie ’n siekte van die lewer of die bloed nie. 
Hierdie organe funksioneer normaal. ‘n Groot hoeveelheid stowwe, genaamd porfiriene, 
hoop in die liggaam op en dit kan twee probleme veroorsaak - verhoogde sensitiwiteit 
van die vel tot sonlig; en 'n komplikasie wat ‘n akute aanval van porfirie genoem word. 
Akuut-intermitterende porfirie (AIP) is nie die mees algemene vorm van porfirie in Suid-
Afrika nie. Mense met AIP ontwikkel slegs een komplikasie van die siekte, en dit is die 
akute aanval van porfirie (sien hieronder).  Baie mense met AIP het nooit enige 
probleme en na hulle word verwys as draers van die siekte. Hulle bly vatbaar vir 'n 
akute aanval en moet die nodige voorsorgmaatreëls tref. Hulle word beskryf in ons 
porfirie inligtingstuk. 
 
Oorerflikheid van AIP 
AIP word oorgeërf as 'n outosomaal dominante toestand. Dit beteken die siekte word 
oorgedra van een generasie na die volgende en elkeen van die nasate het ‘n 50% kans 
om die defektiewe geen te hê. Wanneer ’n enkele kopie van die defektiewe geen geërf 
word, word die persoon gewoonlik nie siek nie – ’n mens moet twee kopieë van die 
betrokke geen hê. Met ander woorde, ’n mens kan die geen erf met geen teken van die 
siekte nie. Kinders kan egter die mutatie weer na hul eie kinders oordra. 
Ons vermoed dat daar baie verskillende mutasies in Suid-Afrikaanse pasiënte met AIP 
is (die 4 mutasies wat tot op hede geïdentifiseer is, verskil van mekaar). Dit beteken dat 
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die verskillende families nie aan mekaar verwant is, en dit kan net deur kans wees dat 
hulle die siekte ontwikkel het. 
 
Kliniese manifesterings: 
Pasiënte met AIP ontwikkel nie velsiekte nie. Dit beteken dat hul vel nie meer sensitief 
vir die son as gewoonlik is nie. 
Hulle is egter vatbaar vir 'n akute aanval. Sommige pasiënte kry kort-kort aanvalle. 
Hierdie pasiënte benodig spesiale behandeling en hul dokters word aangeraai om ons 
sentrum te kontak vir hulp en advies (www.porphyria.uct.ac.za). In ’n noodgeval, kontak 
Groote Schuur Hospitaal (021-404 9111) en vra vir die lewer-dokter / -konsultant aan 
diens. Daar is egter pasiënte wat 'n mutasie erf en nooit enige probleme ontwikkel nie 
(draers). 
 
Diagnose van AIP 
Omdat AIP nie algemeen in Suid-Afrika is nie (dit is baie minder algemeen as Porfirie 
Variegata),  word dit dikwels nie gediagnoseer nie. 
Om 'n diagnose van AIP te bevestig moet sekere  toetse in ‘n betroubare laboratorium 
gedoen word. In families waar die mutasie nie bekend is nie, sal roetine toetse van 
urien, stoelgang en bloed gedoen word. Kliniese en familie inligting help om die 
interpretasie te maak. 
DNA toetse is nie beskikbaar vir roetine AIP diagnose nie. Maar as die mutasie in ’n 
familielid geïdentifiseer word, kan andere familielede getoets word op enige ouderdom. 
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Voorsorg vir mense met AIP 
Probeer om oorsake wat ’n akute aanval kan uitlok, te vermy. Vermy alle medikasie wat 
gevaarlik is in porfirie (sien boekie). Dra ’n Medic-Alert armband wat sê dat jy aan 
porfirie ly. Lig jou dokter, tandarts en apteker in dat jy aan porfirie ly, om te voorkom dat 
jy onveilige medisyne kry. Raai alle familielede aan om getoets te word omdat hulle die 
mutasie kan hê en in die toekoms simptome kan ontwikkel. 
 
Wat is 'n akute aanval? 
Pasiënte met AIP het altyd 'n risiko om 'n akute aanval van porfirie te ontwikkel. Dit kan 
baie gevaarlik wees, dus is dit belangrik dat ‘n mens verstaan hoe so 'n aanval voorkom 
kan word. Die akute aanval kom voor wanneer die vlak van porfirie-voorlopers (ALA en 
PBG) baie hoë vlakke bereik - veel hoër as normaal. Volledige besonderhede van die 
akute aanval en hoe om dit te verhoed word beskryf in die porfirie boekie. 
 
Hierdie studie 
Hierdie studie het ten doel om die DNA mutasie wat jy het en wat AIP veroorsaak, te 
identifiseer. Ons sal jou vra of ons bloed by jou kan trek (2 x 4.5 ml). Die DNA sal uit die 
bloed onttrek word en gebruik word om die presiese mutasie te identifiseer. 'n 
Siftingstoets sal dan opgestel word sodat die ander lede van jou gesin maklik getoets 
kan word. Dit is belangrik omdat ongeïdentifiseerde familielede die kans het om 'n akute 
aanval te ontwikkel. Sodra die mutasie geïdentifiseer is, en jy die resultaat wil hê, sal 
die uitslag en genetiese voorligting aan jou beskikbaar gestel word. 
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ADULT CONSENT FORMS (ENGLISH) 
 
Molecular characterisation of acute intermittent porphyria in South Africa 
CONSENT FOR DNA ANALYSIS AND STORAGE (BY PATIENTS AND FAMILY 
MEMBERS) 
 
1. I, _____________________________________________________, request 
that use be made of my DNA to identify the disease causing mutation for acute 
intermittent porphyria that:  I/my child (DELETE WHERE NOT APPLICABLE) 
have/might have inherited. 
  
2. I understand that the genetic material for analysis is to be obtained from:  blood 
cells/previously frozen transformed lymphoblasts (DELETE WHERE NOT 
APPLICABLE). 
 
3. I request that no portion of the sample be stored for later use. o  (MARK IF 
APPLICABLE ). 
 Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT 
APPLICABLE): 
( a )  possible re-analysis 
( b )  other porphyria research, subject to the approval of the University of Cape Town 
Research Ethics Committee, provided that any information from such research will 
remain confidential 
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4. The results of the analysis carried out on this sample of stored biological material 
will be made known to me via GSH/UCT Liver Clinic Doctor or researcher                    
Dr P Fortgens, in accordance with the relevant protocol, if and when available. 
 
5. In addition, I authorise that results may be made known to:  (DELETE WHERE 
NOT APPLICABLE): 
a. other doctors involved in my care 
b. the following family members:   ___________________________________ 
  
6. I authorise/do not authorise my doctor(s) (DELETE WHERE NOT APPLICABLE) 
to provide relevant clinical details to the Porphyria laboratories/Liver Clinic GSH /UCT. 
 
7. I have been informed that: 
( a ) the analysis procedure is specific to the genetic condition mentioned above 
and cannot determine the complete genetic makeup of an individual. 
( b ) the Porphyria laboratories are under an obligation to respect medical 
confidentiality. 
(c) I may withdraw my consent at any time without this affecting my future 
medical care. 
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8. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I 
UNDERSTAND AND MY QUESTIONS ANSWERED BY: 
 ____________________________    DATE:     __________________ 
 
Patient signature ____________________Witnessed consent_______________   
 
Prof P.N. Meissner Mrs L. Emjedi 
Division of Medical Biochemistry Faculty of Health Sciences 
Clinical and Laboratory Sciences Human Research Ethics Committee 
Room 6.09, Level 6 Falmouth Building Groote Schuur Hospital, Observatory 
UCT Medical School Cape Town, 7925 
Observatory, Cape Town 7925 Tel. 27 21 4066338, Fax. 27 21 4066411 
Tel. 27 21 4066206 Email: Nosi.tsama@uct.ac.za  
Email: Peter.Meissner@uct.ac.za	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CONSENT TO PARTICIPATE IN A STUDY 
 
Study: Molecular characterisation of acute intermittent porphyria in South Africa 
Subjects: Individuals with AIP and family members  
This study has received ethics approval from the University of Cape Town (UCT), 
research Ethics Committee no ………………………….. 
All individuals participating in this study are asked to read, complete and sign this form 
on receiving the relevant information on the study. 
Lab code  ……………..   DNA sample no. ………………     
I …………………………………………………(name of  person giving consent), 
hospital folder number  .……………………..(if applicable) hereby agree to participate in 
the study. 
Participant:  (Relationship to person giving consent if not yourself)…………………… 
Name (1)…………………………………………………………………………….………… 
Name (2)…………………………………………………………………………….………… 
Name (3)………………………………………………………………………………………  
Name (4)………………………………………………………………………………………. 
I understand that 2 x 4.5ml blood samples will be taken from me and the sample will be 
used to investigate the genetic factors involved in acute intermittent porphyria (AIP). 
I acknowledge that I have been supplied with information regarding AIP and the nature 
of the study. 
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I have been informed that: 
• I am encouraged to ask questions regarding porphyria and the present research 
study 
• The only discomfort associated with this study is a needle prick when blood is 
taken 
• I will not receive any reward for taking part in this study 
• I am at liberty to refuse to participate/withdraw my consent from this research at 
any time, and this will not affect my relationship with the UCT/GSH Liver Clinic, 
my future medical care, or legal rights 
• The benefit to my participating in the study is that the specific mutation causing 
my AIP will be identified, and will enable a simple test to screen for this mutation 
in my family, allowing an easy diagnosis to be made 
• The study will be done in the Porphyria laboratories, Dept. of Medicine, UCT.  It 
will be done by Dr P. Fortgens and Dr A. Corrigall and led by Prof P. Meissner.  
The study will commence once Ethics permission has been granted 
(approximately July 2010) and will continue for a period of 3 years. 
• If I have any questions about the study I should contact Dr P. Fortgens (tel 021-
4044135) 
 
Please initial each of the following paragraphs if you agree: 
………My doctor may provide clinical information about my condition to the doctors 
involved in this study, on request. 
………I request that results that may have relevance to myself or my family should be 
made known to me. 
………My clinical information and laboratory results may be kept in a computer 
database. I understand that confidentiality will be maintained and that my information 
will not be given to any person not associated with the specific purpose of studying AIP. 
 
	   93	  
Signature of young person giving consent…………………………………….. 
Date……………………………………………. 
Signature of witness………………………………………………………………  
Date………………………………………….…….. 
Contact details of witness…………………………………………………..……. 
NB: Three copies should be signed for:  (1) patient, (2) researcher, (3) hospital folder (if 
applicable). 
 
Prof P.N. Meissner Mrs L. Emjedi 
Division of Medical Biochemistry Faculty of Health Sciences 
Clinical and Laboratory Sciences Human Research Ethics Committee 
Room 6.09, Level 6 Falmouth Building Groote Schuur Hospital, Observatory 
UCT Medical School Cape Town, 7925 
Observatory, Cape Town 7925 Tel. 27 21 4066338, Fax. 27 21 4066411 
Tel. 27 21 4066206 Email: Nosi.tsama@uct.ac.za  
Email: Peter.Meissner@uct.ac.za	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ADULT CONSENT FORMS (AFRIKAANS) 
 
Molekulêre karakterisering van akuut-intermitterende porfirie in Suid-Afrika 
TOESTEMMING VIR DNA-ANALISE EN BERGING (DEUR PASIËNTE EN FAMILIE) 
 
1. Ek, _____________________________________________________, gee hiermee 
toestemming dat my DNA gebruik mag word om die mutasie wat akuut-intermitterende 
porfirie veroorsaak, te identifiseer; wat: ek / my kind (HAAL DEUR WAAR NIE VAN 
TOEPASSING) kon erf.  
 
2. Ek verstaan dat die genetiese materiaal vir die analise verkry sal word van: 
bloedselle / voorheen bevrore getransformeerde limfosiete (HAAL DEUR WAAR NIE 
VAN TOEPASSING).  
 
3. Ek versoek dat geen gedeelte van die monster geberg mag word vir latere gebruik 
nie.  (KRUIS INDIEN VAN TOEPASSING).  
Of  
Ek versoek dat 'n gedeelte van die monster vir onbepaalde tyd geberg mag word (HAAL 
DEUR WAAR NIE VAN TOEPASSING) vir:  
(a) moontlike verdere analise  
(b) ander porfirie navorsing, onderhewig aan die goedkeuring van die Universiteit van 
Kaapstad se Etiekkomitee, op voorwaarde dat enige inligting van sodanige navorsing 
vertroulik sal bly. 
 
	   95	  
4. Die resultate van die analise wat uitgevoer is op die gebergde biologiese materiaal 
bekend gemaak sal word aan my via die GSH / UK Lewerkliniek se dokter, of navorser, 
Dr P Fortgens, in ooreenstemming met die betrokke protokol, as wanneer die resultaat 
beskikbaar is.  
 
5. Verder gee ek toestemming dat resultate bekend gemaak mag word aan: (HAAL 
DEUR WAAR NIE VAN TOEPASSING):  
a. ander dokters wat my behandel 
b. die volgende familielede: __________________________________________ 
 
6. Ek gee toestemming / weier dat my dokter(s) (HAAL DEUR WAAR NIE VAN 
TOEPASSING) relevante kliniese inligting mag verskaf aan die Porfirielaboratorium / 
Lewerkliniek GSH / UK. 
 
7. Ek neem kennis dat:  
(a) die proses van analise spesifiek is vir die genetiese toestand hierbo genoem; dit kan 
nie die volledige genetiese samestelling van ’n indiwidu bepaal nie.  
(b) die Porfirielaboratorium onder 'n verpligting is om mediese vertroulikheid te 
respekteer. 
(c) ek my deelname aan hierdie studie op enige tydstip kan stop, sonder dat dit gevolge 
inhou vir my toekomstige mediese sorg. 
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8. ALLES HIERBO IS AAN MY VERDUIDELIK IN ‘N TAAL WAT EK VERSTAAN EN 
MY VRAE IS BEANTWOORD DEUR: 
____________________________ Datum: __________________  
 
Pasiënt handtekening ____________________Getuie handtekening_______________  
 
Prof P.N. Meissner Mev. L. Emjedi 
Division of Medical Biochemistry Faculty of Health Sciences 
Clinical and Laboratory Sciences Human Research Ethics Committee 
Room 6.09, Level 6 Falmouth Building Groote Schuur Hospital, Observatory 
UCT Medical School Cape Town, 7925 
Observatory, Cape Town 7925 Tel. 27 21 4066338, Fax. 27 21 4066411 
Tel. 27 21 4066206 Email: Nosi.tsama@uct.ac.za  
Email: Peter.Meissner@uct.ac.za	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TOESTEMMING OM DEEL TE NEEM AAN DIE STUDIE 
 
Studie: Molekulêre karakterisering van akuut-intermitterende porfirie (AIP) in Suid-
Afrika 
Deelnemers: Pasiente met AIP en familielede 
Hierdie studie het etiese goedkeuring ontvang van die Universiteit van Kaapstad (UK), 
navorsing Etiekkomitee nr. ... ... ... ... ... ... ... ... ... ... .. 
Alle pasiente wat deelneem aan hierdie studie is gevra om die vorm te lees en te 
onderteken met ontvangs van die inligtingstuk oor die studie. 
Lab-kode ... ... ... ... ... .. DNA-monster nr. ... ... ... ... ... ... 
Ek ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... (naam van persoon wat 
toestemming gee), 
hospitaalnommer ... ... ... ... ... ... ... ... .. (indien van toepassing) stem hiermee toe om 
deel te neem aan die studie. 
Deelnemer (Verwantskap aan persoon wat toestemming gee indien nie self)........... 
........................................................... 
 
Naam (1)........................................................................................................................... 
Naam (2)........................................................................................................................... 
Naam (3)........................................................................................................................... 
Naam (4)........................................................................................................................... 
Ek verstaan dat 2 x 4.5ml bloedmonsters geneem sal word en die monster gebruik sal 
word om die genetiese faktore betrokke in AIP te ondersoek. 
Ek erken dat ek voorsien is met inligting aangaande AIP en die aard van die studie. 
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Ek is in kennis gestel dat: 
• Ek aangemoedig is om vrae te vra oor porfirie en die huidige navorsingstudie. 
• Die enigste ongemak wat verband hou met hierdie studie 'n naaldprik sal wees 
wanneer bloed geneem word. 
• Ek sal nie 'n beloning ontvang vir deelname aan hierdie studie nie. 
• Ek is vry om te weier om deel te neem/my toestemming om deel te wees van die 
navorsing enige tyd te onttrek, en dit sal geen invloed op my verhouding met die 
Universiteit van Kaapstad / GSH Lewerkliniek, my toekomstige mediese sorg, of wetlike 
regte hê nie. 
• Die voordeel van my deelname aan die studie is dat die spesifieke mutasie wat my 
AIP veroorsaak geïdentifiseer sal word, en 'n eenvoudige toets sal dit moontlik maak om 
hierdie mutasie in my gesin te diagnoseer. 
• Die studie sal gedoen word in die Porfirielaboratorium, Dept van Geneeskunde, 
Universiteit van Kaapstad. Dit sal gedoen word deur Dr P. Fortgens en Dr A. Corrigall 
en word gelei deur Prof P. Meissner. Die studie sal begin sodra etiese goedkeuring 
verkry is (ongeveer Julie 2010) en sal voortgaan vir 'n tydperk van ongeveer 3 jaar. 
• As ek vrae het oor die studie het, kan ek kontak maak met Dr P. Fortgens (tel 021-
4044135). 
 
Parafeer asseblief elk van die volgende paragrawe: 
.................My dokter kan kliniese inligting oor my toestand voorsien aan die dokters wat 
betrokke is in hierdie studie, op aanvraag. 
.................Ek versoek dat resultate wat relevant is vir my en my familie bekend gemaak 
sal word aan my. 
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.................My mediese inligting en die laboratorium uitslae mag gehou word in 'n 
rekenaar databasis. Ek verstaan dat vertroulikheid gehandhaaf sal word en dat my 
inligting nie gegee sal word aan enige persoon wat nie verbonde is aan die studie nie. 
 
Handtekening van persoon wat toestemming ………………………………………….…… 
Datum…………………………………………… 
Handtekening van getuie………………………………………….…………………………… 
Datum…………………………………………… 
Kontakbesonderhede van die getuie………………………………………….………………. 
LW: Drie afskrifte moet onderteken word: (1) pasiënt, (2) navorser, (3) hospitaal  (indien 
van toepassing). 
 
Prof P.N. Meissner Mev. L. Emjedi 
Division of Medical Biochemistry Faculty of Health Sciences 
Clinical and Laboratory Sciences Human Research Ethics Committee 
Room 6.09, Level 6 Falmouth Building Groote Schuur Hospital, Observatory 
UCT Medical School Cape Town, 7925 
Observatory, Cape Town 7925 Tel. 27 21 4066338, Fax. 27 21 4066411 
Tel. 27 21 4066206 Email: Nosi.tsama@uct.ac.za  
Email: Peter.Meissner@uct.ac.za	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Ethics Approval 
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Detailed Methods 
 
 
Selection of Study Cohort 
The University of Cape Town Lennox-Eales porphyria laboratory is a national referral centre for 
porphyria diagnosis and management. A total of 29 patients with a clinical and biochemical 
diagnosis of acute intermittent porphyria were designated as potential participants in this study. 
Of these, 10 patients were ultimately recruited and of these, 6 previously had DNA stored for 
further study, and 4 were newly recruited. The remaining patients were not traceable. Of the 10 
participants, 4 were black, 3 of mixed-race and 3 of Caucasian origin. Informed consent was 
obtained from the 3 of the newly recruited patients, while analysis of the HMBS gene of the other 
7 participants was considered imperative for confirmation of diagnosis. Ethical approval for this 
study was obtained from the Health Sciences Faculty Research Ethics Committee (HREC/REF: 
324/2010). 
 
Isolation and Storage of DNA 
On receipt of blood samples (ethylenediaminetetraacetic (EDTA) acid additive) in the laboratory, 
each patient was numerically coded, and such codes were further used in the study. The 
information chain linking patient identity to the coded specimens was known only by the 
researchers participating in the study. 
 
Genomic DNA was isolated from 3.0ml whole blood, using the Wizard Genomic DNA 
Purification kit (Promega, Madison, USA) as per the manufacturer’s protocol (see Appendix B) 
and quantified with the Nanodrop 2000 (Wilmington, USA).  The purity of DNA was assessed 
on the basis of the optical density (OD)260/280 ratio obtained,  and only DNA with an OD260/280 
ratio of 1.5–2.0 was utilised. Aliquots of the DNA samples were diluted to 100-150ng/µl and 
stored at -20°C for the duration of the project. 
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Primer Design and Polymerase Chain Reaction 
The genomic sequence of the HMBS gene was obtained from both the National Centre for 
Biotechnology Information website (http://www.NCBI.nlm.nih.gov) and the ENSEMBL website 
(http://www.ensembl.org/index.html) and annotated using information from both these sites 
(Appendix A). 
 
PCR primers were designed using Primer Designer version 2.0.  Primer Designer allows for the 
specification of certain parameters such as primer length and melting temperature.  
OligoAnalyzer was used to confirm melting temperatures and detect homodimers and 
heterodimers (http://eu.idtdna.com/analyzer/applications/oligoanalyzer). At least 55 base pairs 
(bp) of the flanking intronic regions were included in the amplicons, as splicing regulatory sites 
commonly occur within 40 bases from the exon splice sites. In addition, to assess primer 
specificity for the target sequences, the primer sequences were compared to the rest of the human 
genome, using the Basic Local Alignment Search Tool (http://www.NCBI.nlm.nih.gov/BLAST) 
and checked for single product formation by e-PCR (NCBI). Primers were synthesized by 
Integrated DNA Technologies, Inc (Coralville, USA). Further criteria for the design of primers, 
as well as primer sequences and information, are listed in Appendix B. PCR reactions were 
performed (Appendix C) and products subjected to 3% agarose gel electrophoresis (Appendix D) 
to assess products for purity. 
 
Sequence Analysis 
PCR products spanning all exons of the entire HMBS gene were subjected to direct sequencing, 
to determine the precise sequence variations. PCR products (40µl) were purified for sequence 
analysis (Appendix E) using the GFX PCR DNA and Gel Band purification kit (GE Healthcare, 
Buckinghamshire, UK). Purified samples were then sequenced in both forward and reverse 
directions on an ABI 3130 XL DNA automatic sequencer using a Big Dye terminator cycle 
sequencing kit, by the Department of Genetics, University of Stellenbosch, Stellenbosch, South 
Africa. Sequence data were collected and analysed using BioEdit Sequence Alignment Editor, 
Version 5.0.9.1 (Tom Hall, North Carolina State University, USA). Sequences in BioEdit were 
aligned with Genbank data (http://www.NCBI.nlm.nih.gov) using ClustalW 
(http://dot.imgen.bcm.tmc.edu:9331/multi-align/Options/clustalw.html). 
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Restriction Enzyme Digestion 
Sequence analysis revealed 3 unpublished mutations. The absence of these mutations 
(Appendix H) was confirmed in at least 50 race-matched anonymised control DNA specimens 
(previously obtained from the Western Province Blood Transfusion Service laboratories) by 
restriction enzyme digest analysis (Appendix F). The DNA of family members of 2 related 
probands was also interrogated with restriction analysis. Restriction enzyme maps for wild type 
and polymorphic DNA fragments were constructed using Webcutter 2.0 (copyright 1997, Max 
Heiman) (Appendix F). 
 
HMBS Enzyme Assay 
In two patients sequence analysis revealed no mutations. At the time of this study one of these 
patients had recently deceased, but the other patient was traced and HMBS enzyme activity 
determined1 (Appendix G). 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1Piepkorn MW, Hamernylk P, Labbé RF. Modified erythrocyte uroporphyrinogen I synthase assay, and its clinical 
interpretation. Clin Chem 1978;24:1751-1754. 
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Appendix A 
 
 
Genomic sequence of the HMBS gene illustrating the positions of exons and flanking primers. 
The exon1 forward primer is not represented, and some forward and reverse primers may 
overlap, but both can be viewed in Appendix B. 
 
   1 ccggaagtgacgcgaggctctgcggagaccaggagtcagactgtaggacgacctcgggtc 
  61 ccacgtgtccccggtactcgccggccggagcccccggcttcccggggccgggggacctta 
 121 gcggcacccacacacagcctactttccaagcggagccatgtctggtaacggcaatgcggc  EXON1 
 181 tgcaacggcggtgagtgctgagccggtgaccagcacactttgggcttctggacgagccgt 
 241 gcagcgattggccccaggttgccatcctcagtcgtctattggtcagaacggctatctttt 
 301 tttttttttttttttttttttttttggtccgagtagcttttaaagggccagtagctcggt 
 361 tgccctccggaaggaatggggaaatcagagagcggtgatactgggttaagagtggaagga 
 421 ttgtttggaacggaactccggtccctgcgggcatctgggtgggattcccatcaggcctgg 
 481 gatgcacggctctagatttagtgacccagaccaagaacgttcgtctacacagacggggtc 
 541 ctttcattcgaggctgggctgaggcggatgcagatacggcccctttgggaagacacgttc 
 601 cacttttgattcataggagagagtatcagccaagcctccgaactgcacacaaacgtctta 
 661 gaagtgcgccttctttttgtgttatagtggtctcccagccacagccaacgctccaagtcc 
 721 ccagctgtgacacacctactgaattactaccgtgggtgggaggccgccgtgggcctttcc 
 781 attacgagcctgcttgccgagccctgggcttgtgcacagacaaactgcagagctggtgga 
 841 ggccactgccaggccgagataagaaagagatggggagctgctaatctccccctgtccagc 
 901 ctgttggtgagggctgggatctttgctcttgcagtcattccagagccctggactaggagt 
 961 aggaagatctgaattgtggccccaactctctttcggttattagctctgtgaccctaggca 
1021 agtcacctcatcccttgatgccacccgttgcttctgtaacatggtcccaaaggtgcctgt 
1081 cttgtccacctgataggatttttgagacgacaacaatatgcaaaagcaatagcttcaaca 
1141 tagaagtgctcagtgttttattttttaatgaaacggtttgacttggatatgctgtgcaca 
1201 ttcaatgaacttaaggaattgtttgaacctagtagttctgggaccttagagtcctttctg 
1261 tgggctccctgtggcccagaattttggtggccacgtttaatatcaagcctagcctaattt 
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1321 gcaaagggtctcccagggttaatttattggagtgatcacatggagtagaccagagtctga 
1381 gggcagaaagctgtcacctgcttcggcaatagaggccccagatgtctgggtgcaaaagaa 
1441 ctccatagcaccccgaccaacatggtgaaaccccgtctctactaaaaatataaaaattag 
1501 gccgggcacagtggctcatgcctgtaatcctagcactttgggaggccgaggcaggtggat 
1561 tgcctgagctcaggagttcgagaccagcctagggaacacagtgaaaccccgtttctacta 
1621 aaaatacaaaaaattagccgacgtggtggcatgcgcctgtagtcccagctacttgggagg 
1681 ctaagacaggagaatcgcttgaacctgggaggtggaggttgcactgagccgagaccgcgc 
1741 cattgcactccagcctgggtgacagagcgcgactccccctcaaaaaaagaaaaaaaaaaa 
1801 aaatatatatatatatatacacacacacacatattttagctgggcatggtggtgtgcgtc 
1861 tgtagtagtcccagctacttgggaggctgagtcaggagaatcgcttgaacctggaaggca 
1921 gtggttgtagttagctgagaacatgccactgcactccagcctgggcaacagagggagact 
1981 ctgtctcaaaaaaaaaaaaaaaaggaactacataggatgaacatcccagatcagggaatg 
2041 ttgactgtcgacagtatcagtatctacagtggctactgtctgatgtagaaagaaatggga 
2101 tcaggctaggcgtggtggctcacgcctgtaatcccagcactttgggaggctggggcagga 
2161 ggatcacaagttcgagaccagcctggccaacacagtgaaaccccgtctctactaaaaatg 
2221 tgaaaattagctgggcatggtggaacatgcctgtagttccagcttgaacccaggggtgga 
2281 ggttgtagtgagcctagatcacgccactgcactccagcctgagcaaaacagtgagactct 
2341 gtctaaaaaaaaaaaaaaaaaaagagagaaatgggacctccgtcttagactgaagaattc 
2401 agttctacgtgcttagcagtgaatacttttgtccaaggtactctggcaggaggaagaggc 
2461 gtgtcctcttgagttcttgacttgggctctggcctgttaatatttccatgttggtgaaac 
2521 cagaggcagcactctaggtgcacgaactttaggcagcgcagcctcctagtcttatggaac 
2581 atctgaggcagaagaaacctgagtccaaccttttcattttatagatgaacaaacagatcc 
2641 tggtgggacagtgtacccaaggtcacccagccaagaggctgagcaggactgtacgtcaga 
2701 tccgtttacctcagtccttaatgcatgcagtccagccagattaagggacccttaatactg 
2761 tcagctttccccactgtgggatcttcatcctcttgacttcttttgtagccagacatctgg 
2821 gcctcttgctggagaaggtggcagcttgctgctcttagactctagtctactccatgtggc 
2881 atctggatggcactgaaattttctcaagtgccttgtctgttgtagataatgaatctatcc 
2941 tccagtgactcagcacaggttccccagtgtggtcctggctgccctgcccctgccagctgc 
3001 aggccccacccttcctgtggccaggctgatgggccttatctctttacccacctggctgtg 
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3061 cacagcactcccactgacaactgccttggtcaaggtgggcttcagggctcagtgtcctgg  EXON2 
3121 ttactgcagcggcagcaacagcaggtcctactatcgcctccctctagtctctgcttctct 
3181 ggatccctgaggagggcagaaggtactgaggaaggttaaagggaccagccttggagtatt 
3241 tccccactctgagactcagctggccacaggccaggttctgaagttcctttcttccaagcc 
3301 agtgattctggttcttggacaaggtgttgaggaacactagaaacagaggggactgtgacc 
3361 tggggactttttctgcaggaagaaaacagcccaaagatgagagtgattcgcgtgggtacc  EXON3 
3421 cgcaagagccaggtgggtgcaggagccggggtggaggaggtttgtcagaacagttatgat 
3481 gctcacagcatcacaaattgggggactcagagggttagttcctagtatgaaggagatggg 
3541 gtggctgggcgttaagttccccgggaaatggcagattacattctatggcaagatcatccc 
3601 taggctgggaaaattgttggagtgcagagggctcccaagccccttctcatgcccagatgg 
3661 aaattccagtcccttcaggatctgcctaacctgtgacagtctaaagagtctgagccgtgg 
3721 ctgggaagggcaggactaatccaagtctctacccgcagcttgctcgcatacagacggaca  EXON4 
3781 gtgtggtggcaacattgaaagcctcgtaccctggcctgcagtttgaaatcagtgagtttt 
3841 ctggaaaggagtggaagctaatgggaagcccagtaccccgagaggagagaacacaacatt 
3901 tctggctttgcctatagctaaagcccgtcccgctgccccgagattccttctgggctgctc 
3961 ccagttctgaaggtgctttcctctgaatacctccagctctgactacctggattagcctgg 
4021 catttaacatcttgagctttgggtctttttatgagtgtttctggtcttcctgctcgattg 
4081 tatatactcagagggcaggaaccagggattatgtgcctctgtccccatcatgaatcgtag 
4141 cacagcgctaggctcagtaaatgctgatcaataatgagcacctgattgattgactctctc 
4201 ctcagttgctatgtccaccacaggggacaagattcttgatactgcactctctaaggtaac  EXON5 
4261 aacatcttcctccccagttcttgtccccactcttctttccttccctgaagggattcactc 
4321 aggctctttctgtccggcagattggagagaaaagcctgtttaccaaggagcttgaacatg  EXON6 
4381 ccctggagaagaatgagtaagtaaagataggagagtgtggtgccctcccagtctcttgct 
4441 gggaccctagtatgctaggtctcttgctgggacccggggtgtcagataggctgctgggct 
4501 taaaccctcagagaggctgaaggcagctcataggtgggttttttcaggcttcagaaaagg 
4561 agagtgtctggttctgagccatctggctgcctggactgcaagaatggctgggggagggag 
4621 ggtaggagggagagtaggagggagagtgagaggagagcagttttcatgctcctgagatct 
4681 tgagaaggtgtgcttcctgaactgccctaggctccaccactgaagtagaggcaggggtgg 
4741 gtggagaaggggtgaaggctggctgctcataccctttctctttgcccccctctcccatct 
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4801 ctatagagtggacctggttgttcactccttgaaggacctgcccactgtgcttcctcctgg  EXON7 
4861 cttcaccatcggagccatctgcaagtaagagtcttgcaagtaaggggcttgggcaggggt 
4921 aggcatcatgtgaacctttgcctttccctttggggcctgaccctctgcttcagggttatc 
4981 tcctctgccctgaggagtgttgactggtggcagaaaactcaagaaataccagtgagttgg 
5041 caatcgagagagaatagaggtgatctgaacttaaatctcttccctcattctgtgcccttc 
5101 cctcctcccccaggcgggaaaaccctcatgatgctgttgtctttcacccaaaatttgttg  EXON8 
5161 ggaagaccctagaaaccctgccagagaagaggtaagtggggcctggataggcagcttggt 
5221 gggatgtgcccagaagatgcagggatgggaggaggaggaaaggaacagtgactgcctagt 
5281 gttaaaatctcattgtaacttctctctgggcagtgtggtgggaaccagctccctgcgaag  EXON9 
5341 agcagcccagctgcagagaaagttcccgcatctggagttcaggagtattgtatcctttta 
5401 gaagagtgacggatccttttggaagagtgacggagacagcagccaaggaaaaagacaagg 
5461 tctagagggctctgggagtccggagagtggaaggggcttccagcaagcagcccgtggggt 
5521 cagtggcctgtctgtctttccatgcactcatccgtccactcatttacagtctaatgtttt 
5581 cttagccccagacaagtgttcagagtgcaaggcattggggataatggtgagcaagataaa 
5641 catttccctgcatatgtagagtttacgtcttacttagggataatgcagttatactgaact 
5701 gaatagtgactacttctggagggatagggagtacttccttttttttttttttttttttct 
5761 gagacggagtctcgctctgttgcccaggttggagtgcagtggcgcaatctaggctcactg 
5821 caacttctgcctcctgagttcaagcaatcttcctgcctcagcctcctaagtagttgggat 
5881 tacaggtgccaccacacctggctaatttttgtatttttagtagagactgggtttcaccat 
5941 gttagtcaggctggtctcaaactcctgacctcaggtgatccaccagcctcggcctcccaa 
6001 agggctgggattacaggcttgagccccgcacccggtcagtacttccatttttatatgcta 
6061 ctatattgtcttgacttttacaatgaatatgtagtacatttcataaaactaaatttaaaa 
6121 atagtatgtgctaagtgctccaataagtgaagttgggaattttctggaaacttctagttg 
6181 gaacatctaaacacagaagtctggggtgtcagggaaggtttctcagaggtcttgtaacct 
6241 tggcaagttatttagcctccctatgtcattttccttatctgtaaagtggggataataata 
6301 ctaccttcctcacagggttgttgtgaagatgaaatgagctgacatatggaaagtactttt 
6361 agagcagtgtctggcatgtagtaagtatgatgtaactgttagctgttaacattaagctga 
6421 gagctggaagatgactgaaagtcagccagctagagagggaaagacagactcaggcagagg 
6481 gaaccgcacgaggccccagattgcccgacactgtggtccttagcaactctccacagcggg  EXON10 
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6541 gaaacctcaacacccggcttcggaagctggacgagcagcaggagttcagtgccatcatcc 
6601 tggcaacagctggcctgcagcgcatgggctggcacaaccgggtggggcaggtagggcctg 
6661 cccctatcctctccccagctcatctgcatctcctttctgccttacagtcatccccaattt 
6721 aggatttttagactttatgattgtgtgaaagcgatatacgttcagtagaaactgtactta 
6781 gtacccatacagccattctgttttttactttcagtacagtattcattacatgagatattc 
6841 actttattgtaaaacaggcttggtgtcagatgattttgtccaactataataggctaatct 
6901 taagtgttctgagcacatgtaaggtaggctaggtgtattaaatgcattttcagcttgttt 
6961 tcaacttaacaatgggtttatcaggatgtaaccctattgtaagtcaaggaccatctgtct 
7021 tcacttcttgaccaccccacctctaacaccgtaggctgggaagattgtgaatcagaggcc 
7081 agactctaggctttcatggagaaaatttacaaaaaaaaaaaaaaagaggccagactcaca 
7141 cttaggcctacccaggctttctagatgatagggaactcccatctcactgccaggtgcttt 
7201 tagacacccccgtgtccacccttttgactccctgttccgcctccacagatcctgcaccct  EXON11 
7261 gaggaatgcatgtatgctgtgggccaggtacacttgaccagggaagccacatggtgacat 
7321 atgccttccctttgttctcaaccaagaagcttgtctcacaaccttctgcatctgcttccc 
7381 cagaatagcattctcagggaggggcagaccttgggatgctaccggtccaaaaggcgctgg 
7441 ggagcaagtagatagaggtggtcccatgctttgcgccattggttggggaaagatcaggcc 
7501 tgatgtcctaggatgtttttccatcagggggccttgggcgtggaagtgcgagccaaggac  EXON12 
7561 caggacatcttggatctggtgggtgtgctgcacgatcccgagactctgcttcgctgcatc 
7621 gctgaaagggccttcctgaggcacctggtagggcctgtgctccacctgtggagggctggg 
7681 gacttggagagctgggaaaggtggcagggaagatttcttacatgaatgctctgtatacag 
7741 tgctaactcattcttgttgaatgttgtgtatggataggaccaggtctgggcccacagttg 
7801 ccttttcagtgatgtcctcaggtctgtggtcacagggtggtgttaagagcccttgcagct 
7861 cacaagaacttcttgttacaggaaggaggctgcagtgtgccagtagccgtgcatacagct  EXON13 
7921 atgaaggatgggcaagtaagtggggggaaatgggcgggaagccagggaaaggaggactgt 
7981 ggcatttcttcctgtgcatcccaggtttctaggtagtcccctctcagactgtgctgaggc 
8041 aactgttttcttccccagctgtacctgactggaggagtctggagtctagacggctcagat  EXON14 
8101 agcatacaagagaccatgcaggctaccatccatgtccctgcccaggtaccaaagctggag 
8161 ggcgagggggtaataaacaagagtgcatataatctcttgttctcaccaaatcccacctcc 
8221 ttccctcatacagcatgaagatggccctgaggatgacccacagttggtaggcatcactgc  EXON15 
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8281 tcgtaacattccacgagggccccagttggctgcccagaacttgggcatcagcctggccaa 
8341 cttgttgctgagcaaaggagccaaaaacatcctggatgttgcacggcagcttaacgatgc 
8401 ccattaactggtttgtggggcacagatgcctgggttgctgctgtccagtgcctacatccc 
8461 gggcctcagtgccccattctcactgctatctggggagtgattaccccgggagactgaact 
8521 gcagggttcaagccttccagggatttgcctcaccttggggccttgatgactgccttgcct 
8581 cctcagtatgtgggggcttcatctctttagagaagtccaagcaacagcctttgaatgtaa 
8641 ccaatcctactaataaaccagttctgaaggtgt 
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Appendix B 
 
 
PRIMER CRITERIA 
• Primer lengths of 18 to 22bp were chosen to ensure specificity.  Shorter primers tend to 
bind non-specifically to the genome 
• Amplicon sizes of no more than  approximately 900bp were chosen, to enable successful 
sequencing of the whole amplicon 
• Melting temperatures (Tm) of 55 to 65°C were chosen. Primers with melting temperatures 
above 65°C have a tendency for secondary annealing 
• The Tm difference between primer pairs was chosen to be preferably no more than 3°C and 
definitely no more than 4°C 
• Primer dimer formation due to complementarity between primers was avoided 
• The possibility of a primer folding back on itself and creating a hairpin loop due to self-
complementarity was examined, and where possible avoided 
• Sequences containing three or more tandem repeats of a single nucleotide (e.g. GGG) were 
avoided where possible as they can misprimed 
• A GC clamp at the 3' end helps promote specific priming due to the stronger bonding of G 
and C bases. However, more than 3 G's or C's should be avoided in the last 5 bases at the 3' 
end of the primer 
• 3’ ends of primers should not be complementary as this may result in primer dimerisation 
• Characteristics of the HMBS gene primers used are summarised in Table 1 
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Table 1: Characteristics of the HMBS gene primers used 
Amplicon Primer 
Pair 
Size 
(bp) 
Product 
Size (bp) 
Tm 
(°C) 
Sequence 
Exon 1 HMBS F1 20 342 58 5’ggtccactgtcgcaatgttc3’ 
 HMBS R1 20   5’tagacgactgaggatggcaa3’	  
Exon 2-3 HMBS 2F 19 902 58 5’gcctcttgctggagaaggt3’	  
 HMBS 3R 19   5’agccacggctcagactctt3’	  
Exon 4-6 HMBS 4F 19 814 58 5’gcctaacctgtgacagtct3’	  
 HMBS 6R 19   5’ccagcagcctatctgacac3’	  
Exon 7-9 HMBS 7F 19 854 58 5’aggctccaccactgaagta3’	  
 HMBS 9R 19   5’tgagtggacggatgagtgc3’	  
Exon 10 HMBS 10F 19 598 58 5’agacagactcaggcagagg3’	  
 HMBS 10R 19   5’ccagcctacggtgttagag3’ 
Exon 11-12 HMBS 11F 19 787 54  5’ctctaacaccgtaggctgg3’ 
 HMBS 12R 20   5’acagacctgaggacatcact3’ 
Exon13-15 HMBS 13F 20 781 58 5’atgtcctcaggtctgtggtc3’ 
 HMBS 15R 20   5’cacatactgaggaggcaagg3’	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Appendix C 
 
 
POLYMERASE CHAIN REACTION 
Reagents 
• Distilled water (dH2O) 
• Mg-free PCR buffer (Promega, Madison, USA) 
• MgCl2 25mM (Promega, Madison, USA) 
• Deoxynucleotide triphosphates (dNTPs; Promega, Madison, USA) 
• Primers (forward and reverse) (Appendix B) 
• Go taq flexi (Promega, Madison, USA) 
 
Method 
• All work was done on ice 
• Gloves were used at all times to prevent contamination 
• A PCR mastermix was prepared in a sterile 1.5ml microcentrifuge tube (Table 2) 
• The mixture was aliquotted into 0.2ml microcentrifuge tubes (49µl per tube) 
• 1µl (100 to 150ng) of genomic DNA was added to each reaction (for one reaction DNA 
was replaced with 1µl dH2O to serve as a negative control) 
• Tubes were briefly vortexed and centrifuged 
• PCR reactions were performed in the thermocycler (Labnet Multigene Optimax) as 
follows: 
o denaturation at 95°C for 1min 
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o 35 Cycles of denaturation at 95°C for 30s, annealing at the specified temperatures 
(Appendix B, Table 1) for 30s and elongation at 72°C for 30s 
o Final elongation at 72°C for 7min 
o PCR products were stored at 4°C until further use 
 
Table 2: PCR reagent mixture per reaction 
Reagent Stock Concentration Volume (µl) Final 
Concentration 
dH2O - 32.8 - 
Buffer 5X 10.0 1X 
MgCl2 25mM 3.0 1.5mM 
dNTPs (Each) 2.5mM 1.0 50µM 
Primers (forward and 
reverse) 
25µM 1.0 0.5µM 
Go Taq Flexi 5U/µl 0.2 1Unit 
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Appendix D 
 
 
AGAROSE GEL ELECTROPHORESIS 
Solutions 
50X Tris acetate-EDTA (TAE) buffer (40mM Tris, 20mM acetic acid, 1mM EDTA, pH 7.6) 
• Tris base        242g 
• Glacial acetic acid      57.1ml 
• 0.5M EDTA        100ml 
• Reagents were diluted to a final volume of 1l with dH2O 
• Prior to use 50X stock buffer was diluted 1:50 with dH2O      
 
Method 
• The gel tray of the gel electrophoresis apparatus (Sub-Cell GT Agarose Gel 
Electrophoresis System; Bio-Rad) was assembled onto a level gel caster and a 15-well 
comb engaged 
• Agarose (1.8g) (Agarose MP, Roche) was weighed into a 250ml Ehrlenmeyer flask and 
60ml of TAE buffer added 
• This mixture was heated in a microwave to boiling point, with intermittent swirling, till all 
agarose was dissolved 
• Ethidium bromide (6µl of 10mg/ml) was added to the dissolved agarose with swirling, 
poured into the gel tray and the agarose allowed to set for 30min 
• The comb was removed, the gel tray placed into the electrophoresis apparatus, submerged 
in TAE buffer (approximately 1 500ml), and the samples (10µl) and 1kb ladder (5µl; 
Promega, Madison, USA) loaded into wells with a 20µl pipette 
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• The lid was secured and electrophoresis performed at 110v for approximately 45min 
• PCR fragments were visualised using the Uvipro gel documentation system and 
photographed for future use 
 
 
POLYACRYLAMIDE GEL ELECTROPHORESIS 
Solutions 
Acrylamide-bisacrylamide (ABA) solution 
• Acrylamide (Promega, Madison, UK)    30%  (60g) 
• Bisacrylamide (Promega, Madison, UK)   0.8%  (1.6g)  
• Made up to 200ml with dH2O 
 
10X Tris borate-EDTA, pH 8.3 
• Tris          540g     
• Boric Acid       275g 
• EDTA         37g 
• Made up to 5l with dH2O and pH adjusted to 8.3 
• Autoclaved for 30min 
 
10% Ammonium Persulphate 
• Ammonium persulphate     1g 
• Made up to 10ml with dH2O 
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Bromophenol blue loading dye 
• Bromophenol Blue      0.25% w/v  (0.25g)   
• Sucrose         40% w/v  (40g) 
• 0.5M EDTA       4ml  
• Made up to 100ml with dH2O 
 
6% Acrylamide Gel 
• 10X Tris borate-EDTA      4ml 
• ABA          8ml 
• Made up to 40ml with dH2O 
 Added to this:  
• Ammonium persulphate      400µl      
• N,N,N´,N´-tetramethylethylenediamine   40µl 
• Mixed well 
 
Ethidium bromide staining solution 
• Ethidium bromide (1mg/ml)     200µl 
• dH2O          200ml 
• Mixed by swirling gently 
 
Materials 
• Hoefer Vertical Slab Gel Unit, SE600 series with gel apparatus (Hoefer, GE Healthcare, 
Vienna, Austria)  
• Hoefer PS1500 DC Power Supply (Hoefer, GE Healthcare, Vienna, Austria)  
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• Hamilton Microliter Syringe (Hamilton Bonaduz AG, Bonaduz, Switzerland) 
• Gel Documentation system, UVItech (UVItech Limited, Cambridge, UK) 
• Mitsubishi P90E(B) Video copy processor (Mitsubishi Electric Corporation, Tokyo, Japan) 
 
Reagents 
• 6% Acrylamide Gel 
• Tris borate-EDTA running buffer (1X) 
• Ethidium bromide (1µg/ml) 
• Bromophenol blue loading dye 
• 100bp molecular weight marker (Promega, Madison, USA) 
 
Method 
• The gel apparatus was assembled by placing two glass plates, separated by 1.5mm spacers 
and secured with clamps, vertically onto a gel stand and secured using cams 
• A 6% acrylamide solution was made up and poured between the glass plates 
• All air bubbles were removed 
• A 20 well 1.5mm gel spacer comb was inserted and the gel allowed to set for at least 
30min 
• The comb was carefully removed from the gel 
• The upper buffer chamber was assembled on top of the gel and clamped into place 
• 500ml of 1X Tris borate-EDTA buffer was poured into the upper buffer tank 
• 5µl DNA was mixed with an equal amount of PCR loading dye 
• Samples were carefully loaded into the wells using a Hamilton syringe 
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• To one of the wells 10µl 100bp DNA step ladder (diluted 1:2 with bromophenol blue 
loading dye) was added to serve as a size standard 
• Samples were run in 1X Tris borate-EDTA running buffer at 270V for 1 to 1.5h 
• The gel was removed and stained in ethidium bromide solution for 10min 
• PCR fragments were visualised using the gel documentation system and photographed for 
future reference 
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Appendix E 
 
 
PURIFICATION OF PCR PRODUCTS FOR SEQUENCING 
Method 
• Capture buffer (500µl ) was added to a 1.5ml microcentrifuge tube 
• PCR product (up to 100µl) was added to the capture buffer and the solution mixed by 
vortexing 
• The solution was added to the GFX microspin column already assembled in a collecting 
tube  and centrifuged (10 000g; 30s) 
• The flow-through was discarded and the GFX column placed back inside the collection 
tube 
• Wash buffer (500µl) was added to the column and centrifuged (10 000g; 30s) 
• The collection tube was discarded and the GFX column transferred to a 1.5ml 
microcentrifuge tube 
• Approximately 30µl of elution buffer type 6 was applied directly to the surface of the 
matrix in the GFX column,  allowed to incubate for 1min at room temperature and 
centrifuged (10 000g; 1min) to recover purified DNA 
• Note: recovery is reduced when using low elution volumes to concentrate DNA 
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Appendix F 
 
 
RESTRICTION ANALYSIS 
Method 
• A restriction enzyme mixture consisting of the appropriate enzyme and corresponding 
buffer (Table 3) was made up in a 1.5ml microfuge tube to a final volume of 10µl per 
reaction with dH2O 
Table 3: Restriction enzyme reagent mixture per reaction 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[E] = enzyme concentration 
U = units 
Polymorphism 
 
Enzyme 
 
[E] 
(U) 
Buffer 
10X (µl) 
Digestion 
Time (h) 
c.292A>G 
Sty1   
(Fermentas, Hanover, 
Maryland, USA) 
1 2 3 
c.689_690delAC  
BstY1  
(Thermo Scientific, 
Vilnius, Lithuania) 
1 2 3 
c.422 + 
3_6delAAGT 
XcmI  
(New England Biolabs, 
Ipswich, MA, USA) 
1 2 3 
c.848G>A 
XbaI   
(Thermo Scientific, 
Vilnius, Lithuania) 
1 2 3 
c.161-1G>A 
DdeI  
(Thermo Scientific, 
Vilnius, Lithuania) 
1 2 5 
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• Restriction enzyme master mix (as per Table 3) was vortexed and spun down briefly in a 
microcentrifuge 
• 10µl of the above mixture was aliquoted into 0.5ml microcentrifuge tubes and 10µl of PCR 
product added 
• After vortexing, a drop of mineral oil was added to the tube followed by a brief spin in a 
microfuge 
• A positive control was included with each set of digests to confirm complete digestion of 
product 
• Restriction digests were incubated at 37°C as indicated (Table 3) 
• Restriction enzyme digests were visualised by agarose or polyacrylamide gel 
electrophoresis (Appendix D) 
 
RESTRICTION MAPS 
Sty1 (Echo130I)  
• Primers: 7F/8-9R 
• Fragment sizes:   854bp = 735bp + 119bp (wild type (WT) ) 
    854bp = 119bp + 616bp + 119bp (mutated) 
A C T C C T T G A A G G A C C WT sequence 
A C T C C T T G G A G G A C C mutated sequence 
  (c.292A>G) 
• The WT sequence contains one recognition site: c|c w w g g (between the 735bp and 
119bp fragments) where w = a or t 
• The mutation creates a recognition site: c|c w w g g (between the 119bp and 616bp 
fragments of the 735bp fragment) 
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• A second cutting site exists in the mutated sequence (between the 616bp and 119bp 
fragments) 
BstY1 (PsuI)  
• Primers: 11F/12R 
• Fragment sizes:   787bp = 207bp + 325bp + 255bp (WT) 
                            787bp = 207bp + 318bp + 7bp + 255bp (mutated)    
                           A C      deletion 
G G A C C A G G A T C T T G G A T C mutated sequence 
        (c.689_690delAC) 
• The WT sequence contains two recognition sites: r|g a t c y (between the 207bp and 
325bp fragments; and the 325bp and 255bp fragments) 
where r = g or a, and y = c or t 
• The deletion in the mutated sequence introduces a cutting site (in the 325bp fragment) 
XcmI 
• Primers: 7F/8-9R 
• Fragment sizes: 854bp (WT) 
  850bp = 480bp + 370bp (mutated) 
                                          A A G T  deletion 
C C A G A G A A G A G G T G G  mutated sequence 
       (c.422 + 3_6delAAGT) 
• The WT sequence contains no cutting site 
• The mutated sequence introduces a cutting site between the 480bp and 370bp fragments: 
c c a n n n n n|n n n n t g g  where n = any base pair 
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XbaI 
• Primers: 13F/15R 
• Fragment sizes: 785bp = 278bp + 507bp (WT) 
  785bp = 271bp + 7bp + 507bp (mutated) 
 
A G G A G T C T G G A G T C T A G A C  WT sequence 
 
A G G A G T C T A G A G T C T A G A C  mutated sequence 
          (c.848G>A) 
• The normal sequence contains one recognition site: t|c t a g a (between the 278bp and 
507bp fragments) 
• The mutated sequence introduces a cutting site 7bp 5’ of the cutting site in the normal 
sequence 
 
DdeI 
• Primers: 4F/6R 
• Fragment sizes: 814bp = 27bp + 377bp + 66bp + 48bp + 50bp + 67bp + 179bp (WT) 
814bp = 27bp + 377bp + 66bp + 98bp + 67bp + 179bp (mutated) 
 
 T C T C T C C T C A G T T G C T A  WT sequence 
 
 T C T C T C C T C A A T T G C T A  mutated sequence 
         (c.161-1G>A) 
• The normal sequence contains six recognition sites: c|t n a g (which produces seven 
fragments) where n = any base pair 
• The mutated sequence abolishes the cutting site between the 48bp and 50bp fragments to 
create a 98bp fragment 
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Appendix G 
 
 
HMBS ENZYME ASSAY 
Reagents 
• Haemolysing reagent: 0.2ml Triton X-100 and 28.8mg ZnSO4.7H2O were dissolved in 
100ml dH2O, and stored at 4°C. Just prior to use 4mg dithiothreitol was dissolved in 25ml 
of this solution (giving a final concentration of Zn ions and dithiothreitol of 1mM) 
• Reaction buffer: 4.4g Na2HPO4.2 H2O was dissolved in about 80ml of H2O, pH adjusted to 
7.5 with 0.25M citric acid (5.25g citric acid monohydrate dissolved in dH2O and made up 
to 100ml)  and made up to 100ml with dH2O 
• 4mM ALA substrate: 7mg ALA.HCl (Sigma-Aldrich, St Louis, Mo., U.S.A.) was dissolved 
in 10ml reaction buffer 
• Stopping reagent (10%, w/v, trichloroacetic acid): 10g trichloroacetic acid was made up to 
100ml with dH2O 
• Coproporphyrin standard: 1.98mg coproporphyrin (Sigma-Aldrich, St Louis, Mo., U.S.A) 
was dissolved in 50ml of 1.5M HCl with warming, filtered and the final concentration 
(2008ng/ml) determined after measuring the absorbance at 399.5nm and using an 
extinction co-efficient for coproporphyrin (489cm.-1mM-1) 
 
Samples 
• Controls: on the day of the assay blood was drawn into heparinised phlebotomy tubes from 
one healthy volunteer. The sample was transported at room temperature overnight and 
subsequently stored at 4°C for a further 24hrs. The total time from phlebotomy till assay 
was 48hrs 
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• Patient specimen: blood was drawn into a heparinised phlebotomy tube, transported and 
stored as described for the controls 
• The haematocrit was measured on all whole blood specimens 
• Coproporphyrin standard was diluted to 50, 100 and 200ng/ml with 1.5mM HCl 
 
Method 
• Test specimens (patient and three controls) were assayed in duplicate with one blank 
sample: 
   Blank  Test 
Haemolysing reagent  1ml  1ml  
Whole blood (well mixed)  50µl  50µl 
Mix and pre-incubate at 37°C for 30min 
 
10% trichloroacetic acid  2.5ml  nil 
ALA  1ml  1ml 
Mix and incubate at 37°C for 1h 
 
10% trichloroacetic acid  nil  2.5ml 
Stand at room temperature in the dark for 30min 
• Samples were centrifuged to produce a clear supernatant and the fluorescence (arbitrary 
fluorescence units) of the standards, blank and test specimens recorded at an excitation 
wavelength of 405nm and excitation wavelength of 595nm 
• For each of the standards a ratio of concentration (in nmol/l) over arbitrary fluorescence 
units was calculated and an average (S) of the three values generated. Blank fluorescence 
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was subtracted from each of the average of the duplicates for the patient and control 
fluorescence values (F) 
• HMBS enzyme activity was calculated in nmol.h.-1ml-1 red blood cells:  
(F x S x 4.55 x 100) / 0.05 x haematocrit 
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Appendix H 
 
 
RESULTS OF CONTROL SUBJECTS’ RESTRICTION DIGESTS 
Restriction digests, revealing each of the novel mutations discovered during sequence analysis, 
were performed on at least 50 race-matched control specimens: purified DNA was subjected to 
PCR (Appendix C), restriction enzyme digestion (Appendix F) and either agarose or 
polyacrylamide gel electrophoresis for visualization (Appendix D) of digested products.  In all 
cases no mutations were found in the control groups.  Representative electrophoresis gels are 
presented (Figures 1-4). 
 
Figure 1: Restriction digest showing representative control specimens (lanes 2-5) and 
patient specimen (lane 6; c.292A>G) after digestion with Sty1.  DNA size ladder is 
measured in base pairs (lane 1); 6% polyacrylamide gel. 
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Figure 2: Restriction digest showing representative control specimens (lanes 1-3) and 
patient specimens (lanes 4 and 5; c.689_690delAC) after digestion with BstY1.  DNA size 
ladder is measured in base pairs (lane 6); 6% polyacrylamide gel. 
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Figure 3: Restriction digest showing representative control specimens (lanes 1-3) and 
patient specimen (lane 4; c.422 + 3_6delAAGT) after digestion with XcmI.  DNA size ladder 
is measured in base pairs (lane 5); 6% polyacrylamide gel. 
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Figure 4: Restriction digest showing representative control specimens (lanes 1-5) and 
patient specimen (lane 6; c.161-1G>A) after digestion with DdeI.  DNA size ladder is 
measured in base pairs (lane 7); 6% polyacrylamide gel.  
  1    2     3   4    5    6  7  
200 
100 
300 
400 
500 
